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Abstract 
Introduction 
In2017 the International Diabetes Federation (IDF) reported that approximately 425 million 
adults aged 20-79 years were estimated to have diabetes mellitus (DM) worldwide. The non-
enzymatic glycation reactions of proteins such as haemoglobin have been associated with 
the development of diabetic related complications. These reactions were believed to be 
irreversible until the discovery of a protein repair enzyme fructosamine 3 kinase (FN3K). 
This enzyme deglycates glycated haemoglobin (HbA1c) in erythrocytes and other glycated 
proteins in other tissues. Animal model studies found that the activity of this enzyme varies 
between individuals leading to differences in HbA1c levels. This results in discrepancies 
between HbA1c and other glycaemic measures which is termed the glycation gap. The 
glycation gap is consistent over time within individuals and is associated with diabetic 
complications. Genetic variants in the FN3K gene have been associated with altered 
enzyme activity. Therefore, the aim of this study was to examine the role of FN3K genotypes 
on the glycation gap 
Methods 
A  total of 1412 subjects (925 normal, 216 pre-diabetic and 271 type 2 diabetics), with 339 
males and 1073 females aged ≥ 20 years of mixed ancestry descent, residing in Bellville 
South, South Africa were included in this study. The diabetics were diagnosed using the oral 
glucose tolerance test. The glycation gap was determined according to a formula: Glycation 
gap= HbA1c - FHbA1c, (FHbA1c = {[(fructosamine- mean fructosamine)/SD fructosamine] 
X SD HbA1c} + mean HbA1c). DNA was extracted from whole blood using the salt extraction 
method. FN3K single nucleotide polymorphisms (SNPs) were genotyped with the Applied 
Biosystems™ QuantStudio™ 7 Flex Real-Time PCR System 96 well fast from Thermo 
Fisher Scientific. HbA1c was measured using HPLC (Biorad Variant Turbo) and 
fructosamine was measured using a colorimetric test nitro-blue-tetrazolium (NBT).  
Results 
SNP c. -232A/T deviated from Hardy Weinberg Equilibrium (HWE) and was left out for the 
rest of the statistical analysis. The polymorphism G900C followed the Hardy-Weinberg 
Equilibrium and was therefore studied. The genotype frequencies for SNP G900C in the 
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glycaemic sub-groups were as follows, GG: 45.9 %, GC: 43.7 %, CC: 10.4 % in normal 
subjects; GG: 48.6 %, GC: 41.7 %, CC: 9.7% in pre-diabetics and GG: 41.7 %, GC: 46.5 %, 
CC: 11.8 % in diabetics, and they followed the Hardy-Weinberg equilibrium. There were no 
significant differences in the SNP G900C genotype frequencies between the glycaemic sub-
groups. The glycation gap significantly decreased  across the GG, GC and CC genotype 
variants in males, mean ± SD were -0.13±0.86, -0.25±0.72 and -0.80±1.04 respectively, 
(P=0.0239). However the difference was not observed in females. Moreover the glycation 
gap showed a positive correlation with non glycaemic factors including body mass index 
(BMI) (r=0.3694, p<0.0001), waist circumference (waistC) (r=0.3749, p<0.0001), hip 
circumference (hipC) (r0.3151, p<0.0001), triglycerides (r=0.2540, p<0.0001) and a negative 
correlation with high density lipoprotein cholesterol (HDL-Chol) (r=-0.2031, p<0.0001). 
Conclusion 
In conclusion the present study found that the glycation gap might be influenced by genetic 
active mechanisms in the intracellular erythrocyte compartment. Identification of the G900C 
polymorphism in an early stage of diabetes could be useful especially in therapeutic 
decisions and prediction of improved prognosis. However, there are other confounding 
factors influencing the glycation gap and future studies are required to confirm these 
findings. 
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Chapter 1: Literature review 
 
1.1. Diabetes Mellitus 
Diabetes Mellitus (DM) is defined as a disorder of glucose metabolism characterized by 
chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism 
resulting from the inability of the pancreas to produce enough insulin, or when the body 
cannot effectively use the insulin it produces or both (Diabetes care 1997). Insulin is a 
hormone produced in the pancreas by the beta cells in the islets of Langerhans and it 
stimulates the cells in the body to take up glucose from the blood thereby regulating 
carbohydrate, lipid and protein metabolism. Insulin achieves this by binding to cell receptors 
and promoting glucose uptake by mobilizing glucose transporter-4 (GLUT-4) to the surface 
of muscle and adipose tissue. Furthermore, it increases glycogen storage in liver and 
muscle, fatty acids synthesis, and reduces glucose output by the liver (Cartee 2015). 
Therefore, failure to produce insulin or to respond to it can lead to DM and hyperglycaemia. 
Over time, the resulting high glucose levels in the blood damages many tissues in the body, 
leading to the development of microvascular complications involving small vessels 
(retinopathy, nephropathy and neuropathy) and macrovascular complications (myocardial 
infarction, stroke, and arterial disease of the lower extremities) as a result of acceleration 
and exacerbation of atherosclerosis (Seino et al. 2010).  
 
DM accounted for 10.7 % of global all-cause mortality in 2017 among people in this age 
group (IDF 2017). This number was found to be higher than the combined number of deaths 
from infectious diseases (1.1 million deaths from Human Immunodeficiency Virus / Acquired 
Immunodeficiency Syndrome (HIV/AIDS) (WHO 2015), 1.8 million from tuberculosis (WHO 
2016) and 0.4 million from malaria in 2015 (WHO 2015). The African region had the highest 
proportion of people who died from diabetes before the age of 60 in 2017 at 77.0 % (0.23 
million death) (IDF 2017).  
1.2. Classification of DM 
Although all forms of DM are characterized by hyperglycaemia, the mechanism by which 
this develops differs. The classification of DM is based on the cause and the extent of the 
underlying disease process based on the degree of insulin action deficiency. These 
disorders are classified into five groups: the three main types which are type 1 diabetes 
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mellitus (type 1 DM), type 2 diabetes mellitus (type 2 DM) and gestational diabetes mellitus 
(GDM) and less common ones including latent autoimmune diabetes of the adults (LADA) 
and  DM due to other specific mechanisms or diseases. There is also secondary DM which 
arise as a consequent of other diseases such as Cushing’s disease, pancreatitis or due to 
drugs such as corticosteroids, pancreatic cancer is another reason to have diabetes when 
followed by total pancreatectomy and such patients will rely on insulin for the rest of their life 
(IDF 2017). Patients with any form of DM may require insulin therapy; for this reason, the 
previously used terms insulin-dependent diabetes mellitus (IDDM) and non-insulin-
dependent diabetes mellitus (NIDDM)) have been eliminated. 
 
1.2.1. Type 1 diabetes mellitus (Type 1 DM) 
Type 1 DM is less common accounting for only 5 – 10% of cases. It is caused by lack of 
insulin due to pancreatic β-cell destruction as a result of an autoimmune reaction triggered 
by different factors (Imagawa et al. 2003). Markers which identify the autoimmune process 
leading to β-cell destruction include anti-glutamic acid decarboxylase (GAD), islet cell 
autoantibodies (ICA) and / or autoantibodies to insulin (ADA 2006). Therefore, type 1 DM 
can further be classified as autoimmune or idiopathic. When the autoantibodies  are 
identified in the early phase , it is referred to as autoimmune type 1 DM and where they are 
not identified in the early stage it is referred to as idiopathic type 1 DM (Imagawa et al. 2003). 
The development of type 1 DM is associated with certain hereditary factors, such as human 
leucocyte antigen ((HLA) alleles in which the pancreatic β-cells do not secrete adequate or 
no insulin (Knip & Siljander 2008) and environmental factors, such as a viral infection which 
results in the body ‘s immune system attacking and destroying the β-cells of the pancreas 
(Imagawa 2004).   
 
The rate of -cell destruction is variable, being rapid in some individuals (mainly infants and 
children) and slow in others (mainly adults) (Kobayashi et al. 1993). Type 1 DM often 
develops suddenly and presents with symptoms such as excessive thirst (polydipsia) and a 
dry mouth, frequent urination (polyuria), lack of energy, extreme tiredness, constant hunger, 
sudden weight loss and blurred vision (IDF, 2015). Some patients, particularly children and 
adolescents, may present with ketoacidosis as the ﬁrst manifestation of the disease. 
Ketoacidosis is a pathological metabolic acidosis associated with high concentration of 
ketone bodies, caused the breakdown of fatty acids and the deamination of amino acids due 
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to lack of circulating insulin (Dillard-cannon 2014). In severe cases, ketoacidosis can be 
fatal. Ketoacidosis can also develop in T2DM patients requiring insulin therapy for diabetic 
control, but is more common in T1DM (Dillard-cannon 2014). 
 
1.2.2. Type 2 diabetes mellitus (Type 2 DM) 
This is the most common type of DM accounting for 90–95% of cases and is characterized 
by decreased insulin sensitivity (insulin resistance) resulting in relative but not absolute 
insulin deficiency (Hancock et al. 2008). Although the onset of type 2 DM used to be common 
in middle age or later, it is being increasingly described in children and young adults, most 
likely due to an increase in obesity (Hirata et al. 1997).  Type 2 DM frequently goes 
undiagnosed for many years as hyperglycaemia develops gradually and in earlier stages is 
often not severe enough for the patient to notice any of the classic symptoms. The symptoms 
include frequent urination within short intervals, excessive thirst, excessive urge to eat 
(polyphagia), weight loss, blurred vision and increased susceptibility to infections (IDF , 
2015). Hence type 2 DM patients are at increased risk of developing macrovascular and 
microvascular complications. In some instances, the diagnosis of type 2 DM is made at an 
advanced stage when the individual has already developed complications which are 
irreversible or when they are in a coma (Costa et al. 2007). 
 
1.2.3. Gestational diabetes mellitus (GDM) 
GDM is deﬁned as any degree of glucose intolerance that is initially discovered or develops 
during pregnancy. The deﬁnition applies regardless of whether insulin or only diet 
modiﬁcation is necessary for treatment or whether the condition persists after pregnancy 
(Diabetes 2010). Pregnancy triggers the manifestation of a glucose metabolism disorder, 
hence the diagnosis and control of GDM require special considerations, as even a 
comparatively mild disorder in glucose metabolism during pregnancy can exert significant 
influence on the infant and mother (Diabetes care 2010). It may be difficult to distinguish 
GDM from normal pregnancy symptoms, as they may include increased thirst and frequent 
urination (IDF 2015). Screening by means of an oral glucose tolerance test (OGTT) is 
therefore recommended as summarized in table 1.1. This should be conducted early in 
pregnancy for high risk woman (women who are > 25 years of age, overweight or obese, 
have family history of DM, certain ethnicities, previous delivery of a large baby or previous 
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unexplained miscarriage or stillbirth) and between the 24th and 28th week of pregnancy in 
all other women (Rohlfing et al. 2002). Although GDM normally disappears after delivery, 
these women are at higher risk of developing GDM in subsequent pregnancies and type 2 
DM later in life. Babies born to mothers with GDM also have a higher risk of developing  type 
2 DM in their teens or early adulthood (Fetita 2006). 
  
Table 1.1: World Health Organization (WHO) Classification of Hyperglycaemia 
in Pregnancy (WHO 2013) 
 
Fasting plasma glucose (FPG) 5.1-6.9 mmol/L 
 
Or 
One-hour plasma glucose ≥ 10.0 mmol/L following a 75g oral glucose load 
 
Or 
Two-hour plasma glucose 8.5-11.0 mmol/L following a 75g oral glucose load 
 
 
 
1.2.4. Latent autoimmune diabetes of Adults (LADA)  
LADA is a type of DM that develops slowly in adults and is positive for an autoantibody to 
GAD or ICA but does not require insulin-therapy at the time of diagnosis (Zimmet 1995). 
However, unlike the classic type 2 DM patients who are negative for islet autoantibodies, 
LADA patients rapidly become insulin dependent due to the insulin cell attack by their body. 
LADA has been considered as intermediate diabetes due to the fact that it shares 
immunological and genetic aspects with type 1 DM and it affects an age group that is 
typically affected by type 2 DM (Palmer 2003). The Immunology of Diabetes Society 
established the diagnoses of LADA using three main criteria: adult age of onset (>30 years); 
presence of any ICA and absence of insulin requirement for at least 6 months after diagnosis 
(Gottsa et al. 2005). The clinical features of LADA patients include weight loss, susceptibility 
to ketosis, unstable blood glucose levels and extremely diminished C-peptide reserve 
(Kobayashi et al. 1993). 
LADA is not as rare as previously reported, and may be more prevalent than type 1 DM but 
less frequently than type 2 DM (Hawa et al. 2013). LADA may account for 2 - 12 % of all 
cases of DM in adults (Kobayashi et al. 1993; Zimmet 1995; Juneja et al. 2001). The United 
Kingdom Prospective Study of Diabetes (UKPDS) demonstrated that about 10% of adults 
with suspected type 2 DM at the time of diagnosis had evidence of islet autoimmunity in the 
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form of circulating ICA or GAD antibodies and most progressed to dependence on insulin in 
6 years (Turner et al. 1997).  Although both LADA and type 1 DM are autoimmune it has 
been demonstrated that anti-GAD and ICA are much more common than insulin 
autoantibodies (IAA), anti-tyrosine phosphatase (IA-2A), and zinc transporter (ZnT8) 
antibodies in LADA compared to type 1 DM (Juneja et al. 2001; Wenzlau et al. 2008). HLA 
studies may be of value in differentiating between type 1 DM and LADA. LADA has a higher 
frequency of HLA characteristic of type 1 DM: HLA-DR3 (28% of patients), DR4 (27%) and 
DR 3/4 (22%), in comparison to the general population (Cervin et al. 2008). 
1.2.5. Other types of diabetes mellitus  
There are several heredity forms of DM that are associated with monogenetic defects in β 
cell function. They are frequently characterized by onset of hyperglycaemia at an early age 
(generally before 25 years) and are referred to as maturity onset diabetes of the young 
(MODY). They present with impaired insulin secretion with minimal or no defects in insulin 
action. The development of MODY is due to a single abnormal gene - hence it is referred to 
as monogenic DM in order to distinguish it from type 1 DM and type 2 DM which are caused 
by multiple environmental and genetic factors (Yorifuji et al. 2004). MODY is caused by 
mutations in an autosomal dominant gene leading to disruption in insulin secretion 
(Goldstein & Müller-Wieland 2016). There are different types of MODY due to different 
genetic abnormalities as summarized in Table 1.2 (Doria et al. 1999).  
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Table 1.2: Classification of MODY 
Types of MODY Genetic abnormalities 
MODY 1 
MODY 2 
MODY 3 
MODY 4 
MODY 5 
           MODY 6 
Hepatocyte nuclear factor 4 (HNF-4a) 
Glucokinase 
HNF-1a 
Insulin promoter factor-1 (IPF-1) (Pdx-1) 
     HNF-1b 
Neurogenetic differentiation 1 (NeuroD1) /                    
Beta 2 (β2) 
 
Neonatal diabetes  Kir6.2 and sulfonylurea receptor 1 (SUR1) 
(encode subunits of the adenosine triphosphate 
sensitive potassium channel (KATP) in β-cells)  
(Babenko et al. 2006) 
 
 
 
1.2.6. Prediabetes  
This is a state where the blood glucose level is higher than normal but not high enough to 
be classified as DM and is a high-risk state for the development of DM (Nordwall et al. 2015). 
According to the World Health Organization (WHO), prediabetes is classified as one of two 
distinct states: impaired fasting glucose (IFG) with higher than normal glucose levels after a 
period of fasting, or impaired glucose tolerance (IGT) with higher than normal glucose levels 
following OGTT (Imagawa et al. 2003). Although not all prediabetic’s develop type 2 DM, 
they are considered to be at high risk especially those with IGT (Shaw et al. 1999) and also 
have an increased cardiovascular risk (Perry 1999). 
Prediabetics are often asymptomatic therefore it is important that the health care provider 
excludes prediabetes in high risk individuals such as those with increasing age, weight, 
family history of DM, certain ethnicities and history of GDM (ADA 2010). It has been reported 
that 5-10% of prediabetics develop DM annually (Nathan et al. 2007). Approximately 352.1 
million people worldwide, namely 7.3% of adults aged 20 – 79 years were estimated to have 
IGT in 2017 (IDF 2017). The number of adults with IGT in Africa is expected to double to 
154.3 million by 2045 with lack of interventions (IDF 2017). However, several studies have 
shown that the prediabetic state is reversible, with lifestyle and drug-based interventions 
Stellenbosch University  https://scholar.sun.ac.za
7 
 
(Ramachandran et al. 2006 ; DPPR 2009). Hence it is important that prediabetics are 
followed up every one to two years and encouraged to undergo intensive lifestyle 
modification.  
1.3. Aetiology 
DM is due to multifactorial aetiologies. The causes of DM may be due to factors such as 
family history, ethnicity, genetic make-up, health and environmental factors. The causes of 
type 1 DM include autoimmunity and genetic factors. However, there are some risk factors 
which may trigger the development of type 1 DM including: viral or bacterial infection, 
chemical toxins within food and unidentified components causing autoimmune reaction by 
triggering the T cells to target the β-cells (Gavin et al. 1997 ; ADA 2010).  Some 
environmental factors may expose the defects in genetics and it has been reported that an 
early introduction of supplementary milk feeding during infancy may increase the risk of type 
1 DM in children carrying HLA class II genotypes than among those with low or decreased 
risk genotypes (Knip et al. 2005).  
The causes of type 2 DM are usually multifactorial. The risk of developing type 2 DM is 
increased by both environmental and genetic factors. The driving factors for the epidemic of 
type 2 DM are mainly obesity which is fueled by sedentary lifestyle, smoking, alcohol 
consumption, diet, decreased exercise level and urbanization (WHO 1994). All these factors 
result in reduced sensitivity of cells to insulin. Furthermore studies have shown that obesity 
itself causes some degree of insulin resistance (ADA 2010) Abdominal obesity is associated 
with increased inflammation and the secretion of adipokines which may predispose an 
individual to DM (Kahn et al. 2006). Multiple genetic factors are also said to be associated 
with reduced insulin secretion or insulin resistance, although the genetics of type 2 DM are 
complex and not clearly defined (ADA 2010).  
1.4. Epidemiology 
In 2017 the International Diabetes Federation (IDF) reported that approximately 425 million 
people or 8.8% of adults 20-79 years worldwide are estimated to have DM with about 79% 
living in low and middle income countries (IDF 2017). The prevalence of DM has increased 
rapidly over the past 5 years, with a global DM prevalence of 382 million, 387 million, 415 
million and 425 million in 2013, 2014, 2015 and 2017 respectively (IDF 2013; IDF 2014; IDF 
2015; IDF 2017). This number is projected to rise beyond 629 million people aged 20 - 79 
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in 2045 if no action is taken (IDF 2017). DM is a major cause of morbidity and mortality 
worldwide. Approximately 4.0 million people aged between 20 and 79 years died from DM 
in 2017, which is equivalent to one death every eight seconds.  
The burden of DM is high in developing countries. In 2017 the IDF indicated that almost 79% 
of diabetics live in low and middle income countries, with two thirds of all cases arising from 
the Asia Pacific region, mainly China and India (IDF 2017). The high prevalence in these 
countries could be due to poor health care facilities such as inadequate diabetic 
management and public diabetes awareness. This is also applicable in African societies 
including South Africa. Another major factor contributing to the increasing rates of DM in low 
and middle income countries is urbanization (Levitt et al. 1999). As populations move 
towards the urban areas particularly in sub-Saharan Africa (SSA), this migration is 
undoubtedly associated with a shift in lifestyle from a relatively healthy traditional pattern, to 
urban areas with high rates of obesity due to increased food quantity and reduced quality, 
low levels of exercise, smoking and increased alcohol availability (Beaglehole & Yach 2003). 
Although, the majority of diabetics in SSA live in the cities, the population mostly (61.3%) 
originate from rural areas. In 2017 the IDF  reported that the African region had the highest 
proportion of undiagnosed DM reported to be over 69.2% of adults (IDF 2017). However, 
the African region had the lowest prevalence of DM with an estimated 15.5 million adults 
aged 20-79 years having DM compared to other regions worldwide (IDF 2017). Therefore 
the high rate of death related to DM in Africa could be due to the fact that most of the 
diabetics are unaware of the disease hence not on treatment. 
South Africa (SA) is one of the countries in Africa with the highest number of people with 
DM. In 2017 the IDF reported that the following countries had the highest prevalence of DM 
in Africa; Ethiopia (2.6 million), SA (1.8 million), Democratic Republic of Congo (1.7 million), 
and Nigeria (1.7 million) (IDF 2017). Several studies have reported that there are marked 
demographic and ethnic variations in the prevalence of DM in SA (Levitt et al. 1993; Motala 
et al. 2003). Motala et al performed a long term follow up study using 1985 WHO diagnostic 
criteria for glucose tolerance based on 75 g OGTT and reported that SA Indians have a high 
crude incidence (9.5%) of type 2 DM which is significantly associated with higher baseline 
blood glucose, body mass index (BMI) and obesity (Motala et al. 2003). The mixed ancestry 
population of SA was reported to have the second highest prevalence of type 2 DM (7.1% 
crude prevalence) after the Indian population but this study was performed 20 years ago 
using the WHO 1985 criteria (Levitt et al. 1999). However, a more recent cross sectional 
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study conducted between 2008 - 2009 in the Bellville South community, in the Western Cape 
province of SA used the updated WHO 1999 criteria and  reported an increased prevalence 
of type 2 DM in individuals of mixed ethnic ancestry aged ≥31 years with a crude prevalence 
of 18.1% (Erasmus et al. 2012). 
1.5. Diabetes diagnostic criteria 
The diagnostic criteria for DM have changed several times over the past decades due to 
increased knowledge and understanding regarding its aetiology and pathogenesis. In the 
1960s the criteria were based on OGTT but they were still not sure of the quantity of glucose 
to be ingested during the test and the diagnostic criteria were not yet standardized (WHO 
1965). The National Diabetes Data Group (NDDG) of the United States of America proposed 
using 75 g OGTT for classification and diagnosis of DM (National Diabetes Data Group 
1979) and this was adopted by WHO in 1980 (WHO 1980). Therefore, OGTT is a diagnostic 
test performed by ingesting a glucose load containing the equivalent of 75 g of anhydrous 
glucose dissolved in water after an overnight fast of about 10-12 hours. For clinical purposes 
the blood samples for glucose determination are taken immediately before and 2 hours after 
the glucose drink. DM is diagnosed when the 2-hour plasma glucose (2h-PG) is greater or 
equal to 11.1 mmol/L (Helminen et al. 2015). The OGTT is used both in clinical practice and 
by researchers to assess glucose tolerance (ADA 2017).  
The OGTT is considered to be a gold standard test for DM diagnosis (Alberti & Zimmet 
1998). The advantage of the OGTT is that it is a minimal risk procedure and it employs 
commonly available laboratory tests and clinical protocols. It is generally accessible for use 
in large-scale clinical and epidemiologic studies and has been widely used in evaluation of 
β cell dysfunction, obesity, prediabetes and DM (Chen et al. 2018). This test is highly 
sensitive and can be used for screening of DM (Seino et al. 2010). It has been confirmed 
that compared to FPG and HbA1c, the 2 hour PG diagnose more people with diabetes (ADA 
2017). An OGTT is the only means of identifying people with IGT and is frequently needed 
to confirm or exclude an abnormality of glucose tolerance in asymptomatic people (WHO 
2006). However, the OGTT is expensive, less reproducibility and inconvenient since it 
requires patients to fast and stay in the clinic for at least 2 hours and morning appointments 
or return visits for confirmatory test (Diabetes Care 2003).  
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In 1980, the WHO included FPG as one of the diagnostic criteria for DM, but they kept 
changing the cutoff (WHO 1980; WHO 1985; WHO 1999) as illustrated in Figure 1.1. FPG 
is a simple blood test performed in the morning after an overnight fast of 10 to 12 hours. DM 
is diagnosed when FPG is greater or equal to 7.0 mmol/L (WHO 1999). In 1999 the WHO 
updated their DM diagnostic criteria and recommended the lowering of the diagnostic value 
of the FPG threshold from 7.8 mmol/l to 7.0 mmol/L because this value was associated with 
an increased risk of microvascular and macrovascular diabetic complications (WHO 1999). 
The FPG is highly vulnerable to a number of pre-analytical variables including recent food 
ingestion, stress, severe illness, and sample storage as well as high within-subject biological 
variability. Also, a morning appointment is required with return visits for confirmatory tests 
making it inconvenient (Diabetes Care 2003).The American Diabetes Association (ADA) 
elected the international Expert Committee (IEC) in 1979 to revise and modify the previously 
recommended diagnostic criteria for DM by the WHO, 1985 and published its 
recommendation in 1997 (James et al. 1997).  
 
 
 
 
Figure 1.1: Change in diagnostic value for FPG 
 
Since then, the only acceptable tests for the diagnosis of DM were based on a 10-hour FPG 
≥7 mmol/l, a 2-hour OGTT ≥11.1 mmol/l or random plasma glucose (RPG) of ≥11.1 mmol/l 
in a patient with diabetic symptoms. RPG is a blood glucose level taken at any time of the 
day with no fasting required. It is performed when the person presents with typical diabetic 
FPG ≥ 7.0 
mmol/l
• WHO 
1980
FPG ≥ 7.8 
mmol/l 
• WHO 
1985
FPG ≥ 7.0 
mmol/l
• WHO 
1999
Stellenbosch University  https://scholar.sun.ac.za
11 
 
symptoms such as polyuria, polyphagia, polydipsia and excessive weight loss. This test is 
convenient but can only be used in symptomatic patients (Helminen et al. 2015). In 2004 
the ADA and WHO reached a similar conclusion on the diagnostic criteria of DM (ADA 2004). 
However, the WHO further proposed a change in the criteria for prediabetes and 
normoglycaemia which differed from that of the ADA as summarized in table 1.3 (WHO 
2006).  
The IEC of the ADA, which includes the International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) and the National Glycohaemoglobin Standardization Program 
(NGPS) recently recommended the use of glycated haemoglobin (HbA1c) as one of the 
diagnostic criteria for DM, with a threshold of ≥6.5% (≥ 48 mmol/mol IFCC) recommended 
to diagnose DM (IEC 2009). This value was chosen due to the fact that the incidence of 
retinopathy, which is a common diabetic related complication, was found to be increased 
after this value (IEC 2009). Subsequently the ADA and WHO modified their diagnostic 
criteria in 2010 and 2012 respectively in order to incorporate HbA1c  as part of the diagnostic 
criteria as summarized in Table 1.3 ( ADA 2010; John 2012). Individuals having HbA1c 
levels ranging from 5.7 to 6.4 % (39-46 mmol/mol IFCC) were classified as prediabetic as 
they are considered to be at risk for developing DM (George & Ja 2017). The value of HbA1c, 
which is equivalent to the internationally used HbA1c (%) defined by the NGSP, is expressed 
by adding 0.4% to the HbA1c (JDS) (%) defined by the Japanese Diabetes Society (JDS). 
It was then recommended that HbA1c testing should be performed using a method that is 
certified by the NGSP and standardized or traceable to the DCCT reference assay (ADA 
2010).  
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Table 1.3: Criteria for normoglycaemia, prediabetes and the diagnosis of diabetes 
                   (Adapted from WHO 2006 and 2011 and ADA 2010) 
 WHO criteria ADA criteria 
 
   
Normoglycaemia 
FPG:  
2h-PG:    
HbA1c:   
 
< 6.1 mmol/L 
< 7.8 mmol/L  
Not specified 
 
 
  
 < 5.6 mmol/L 
 < 7.8 mmol/L 
 < 5.7 %  
 
 
   
Prediabetes (IFG/IGT) 
FPG:  
2h-PG:    
HbA1c:   
  
6.1- 6.9 mmol/L 
7.8- 10.9 mmol/L 
Not specified 
 
5.6 - 6.9 mmol/L 
7.8 - 11.0 mmol/L  
5.7 - 6.4 %  
 
 
   
Diabetes 
*FPG:  
**2h-PG:  
***RPG:   
****HbA1c:   
 
≥ 7.0 mmol/L 
≥ 11.1 mmol/L 
≥ 11.1 mmol/L 
≥6.5 % 
  
 ≥ 7.0 mmol/L 
 ≥ 11.1 mmol/L 
 ≥ 11.1 mmol/L 
 ≥6.5 % 
 
Footnotes:  
 According to the WHO either*/**/***/**** can be used to diagnose diabetes at the initial 
examination of diabetes. 
 For confirmation of the diagnosis of diabetes a re-examination is done by repetition 
of */**/*** on another date but  
 But if for initial examination ***/**** was used, a confirmation should be done with 
either */** since results can’t be reliable on repetition of this tests. 
 For patients presenting with hyperglycaemia symptoms such as thirst, polydipsia, 
polyuria, weight loss or the presence of diabetic retinopathy, diabetes can be 
diagnosed on the first examination with either */**/***.  
 ****Conducted in a laboratory that is NGSP certified and standardized to the DCCT 
assay 
 **** In conditions where HbA1c might be inappropriately low, either */** should be 
used for diagnosis of diabetes  
 Neither of the criteria */**/***/**** is suitable for point of care assays. 
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1.6. Non-enzymatic glycation of proteins 
The non-enzymatic glycation of proteins is a spontaneous reaction that occurs between the 
free aldehyde group of glucose and free amino groups of proteins (Dziedzic et al. 2012). It 
was first described a century ago by Louis Camile Maillard who named it “Maillard reaction”, 
defined as the browning reaction between amino acids and simple carbohydrates (Maillard 
1912). In the early 1980s this reaction by which glucose chemically bind to amino groups of 
proteins, without the aid of an enzyme was renamed non enzymatic glycosylation (Monnier 
& Cerami 1982). However few years later it was renamed non enzymatic glycation reaction 
in order to differentiate it from enzymatic glycosylation which is posttranslational modification 
of proteins catalyzed by specific enzymes (Yatscoff et al. 1984). 
The non-enzymatic glycation reaction is subdivided into early and advanced steps. The 
reaction is initiated by the formation of an imine intermediate referred to as Schiff base. This 
reaction is reversible and occurs over a period of hours. The labile imine will then rearrange 
itself into stable covalently linked reversible Amadori products, over a period of weeks. In 
the advanced step, the Amadori product undergoes polymerization reactions including 
complex rearrangement, cleavage and covalent binding reactions whereby heterogynous 
structures named advanced glycation end products (AGE) which are nonreversible are 
formed (Baynes and Thorpe 2000 ; Monnier 2003). A simplified scheme of the non-
enzymatic reaction is outlined in Figure 1.2. 
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Figure 1.2. Initial steps of the Maillard reaction between lysine and glucose. Adapted from 
(Szwergold et al. 2002). The formation of Schiff bases, fructoselysines and AGE’s are all 
reversible. Step 1 (formation of Schiff bases) is much faster compared to step 2 (formation 
of fructoselysines) and step 3 (formation of AGE’s). 
1.6.1. Glycated haemoglobin (HbA1c) 
HbA1c as defined by IFCC is a haemoglobin molecule with glucose bound to its N-terminal 
valine of the β chain(βN-1-deoxyfructosyl-haemoglobin) (Jeppsson et al. 2002). The HbA1c 
test measures the percent of haemoglobin in circulating erythrocytes that has non-
enzymatically reacted with glucose and represents the average plasma glucose 
concentration for a period of three months, the lifespan of red blood cells (Franco 2012). It 
was discovered in the late 1960s by Samuel Rahbar when he was scanning blood samples 
for novel haemoglobin variants and discovered a blurry band “HbA1c” increased in diabetics 
(Rahbar 1968). However, it was not believed then that HbA1c was a measure of diabetic 
control until a study performed in diabetic and non-diabetic mice using erythrocytes labelled 
with radioactive iron to track the cells ‘age in mice and results described that HbA1c levels 
increased over the lifetime of a cell and importantly HbA1c increased 2.8 times faster in 
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diabetic mice (Koenig & Cerami 1975). HbA1c was then introduced into the clinical 
laboratories for glycaemic monitoring in 1997 although at that time methods displayed poor 
precision and there were no calibrators or material with assayed values for quality control 
purposes (John et al. 2007). 
The evidence to use HbA1c for glycaemic control was based upon the results of the two 
landmark studies, the Diabetes Complications and Control Trial (DCCT) and the UKPDS. 
The DCCT study was performed in young type 1 diabetics and demonstrated that there is a 
continuous increase in the risk of complications with increasing HbA1c values (DCCT 1993). 
The UKPDS study was performed in type 2 diabetics and described that tight glycaemic 
control by maintaining lower levels of HbA1c using an intensive glucose-control treatment 
policy substantially reduced the risk of developing diabetes-related microvascular 
complications (UKPDS 1998). Standardization of HbA1c became an important issue after 
the publication of the DCCT study. The method used to determine HbA1c in this study was 
not suitable as a primary reference method and a purified standard for this method could 
not be prepared. Therefore, the American Association of Clinical Chemistry (AACC) in 1994 
established the NGSP in an attempt to harmonize the HbA1c test results to those reported 
in the DCCT (Little & Goldstein 1995). The NGSP managed to harmonize HbA1c using the 
results from the DCCT study by a nonspecific Bio- Rex 70 ion exchange HPLC. In 1995 the 
standardization system of the JDS used a set of calibrators to harmonize results of HbA1c 
in Japan (Shima 1994) and in 1998 the Swedish Standardization Scheme similarly to NGSP, 
was based on the MonoS HPLC method as designated comparison method (DCM) for the 
harmonization of HbA1c measurements (Jeppsson et al. 1986). 
 
HbA1c was then harmonized to the DCCT, but not yet standardized implying that the 
variation in HbA1c levels were reduced but not yet eradicated. In 1995 the IFCC Working 
Group (IFCC WG-HbA1c) took it upon themselves to initiate the standardization of HbA1c 
by developing a standard, consisting of purified HbA1c and HbA0 as calibrators and a 
primary reference method. They established a laboratory network with two reference 
methods for HbA1c analysis which included mass spectrometry (HPLC-MS) and capillary 
electrophoresis (HPLC-CE), both based on enzymatic cleavage of the haemoglobin 
molecule (Hoelzel and Miedema 1996 ; Finke et al. 1998). However, the results of IFCC 
HbA1c are reported in mmol/mol and when converted to percentage as reported by NGSP, 
it becomes approximately 1.5 - 2% lower than DCCT values in non-diabetic subjects causing 
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confusion for patient and clinicians (Jeppsson et al. 2002). The A1c-derived Average 
Glucose study group (ADAG) performed a study in 507 subjects (type 1 DM, type 2 DM and 
non-diabetics) and found a strong relationship between average glucose and HbA1c 
permitting the use of estimated average glucose (eAG). This made it possible for translation 
of measured  HbA1c so it could be reported in the same units as used for day-to-day 
monitoring of glycaemia (Nathan et al. 2008). However, even after the IFCC had succeeded 
in standardizing most of the assays used in the U.S, the use of HbA1c still had 
disadvantages and it was not suitable as a diagnostic criteria for DM (Genuth et al. 2003) 
until it was accepted in 2009 (IEC 2009).   
The HbA1c test can be performed at any time of the day and does not require a fasting 
sample which makes it advantageous and a preferred test for assessing glycaemic control. 
The use of HbA1c can avoid the problem of day-to-day variability of glucose values. 
Furthermore, less intra-individual variability was observed when compared with FPG and 2-
hour OGTT (WHO 2011). However, HbA1c also has limitations including a lower diagnostic 
performance in specific populations such as pregnant women and non-Hispanic blacks and 
the risk of over diagnosing DM in the presence of iron deficiency anaemia (Lippi & Targher 
2010). In addition, a study performed on our population (mixed ancestry population of 
Bellville South) by Zemlin et al reported that the recommended cut-off point of HbA1c ≥ 6.5% 
to diagnose DM had a low sensitivity for this population and they established that an HbA1c 
level of ≥ 6.1% had a higher sensitivity (Zemlin et al. 2011). HbA1c levels were found to be 
substantially reduced in subjects with increased RBC turnover, end-stage renal disease and 
haemoglobinopathies (Lippi & Targher 2011). Other disadvantages include large analytical 
imprecision when not using HPLC, and the higher costs compared to glucose measurement 
(Rohlfing et al. 2002). However, it has been recommended that the test for HbA1c levels 
should be performed for glycaemic control at least twice yearly in patients who are meeting 
treatment goals and who have stable glycaemic control and quarterly in patients whose 
therapy has changed or who are not meeting glycaemic control (Driskell et al. 2014). In 2009 
the IEC of the ADA introduced the use of HbA1c as a diagnostic tool for DM (IEC 2009).  
1.6.2. Fructosamines  
Plasma proteins also undergo non-enzymatic glycation reaction forming fructosamines and 
/ or glycated albumin (GA) (Zafon et al. 2013). Serum fructosamines refers to all serum 
proteins that undergo glycation whereas serum GA specifically refers to albumin that has 
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undergone glycation (National Institute of Health 2010). Since the major serum protein is 
albumin, which has a half-life of 20 days, both fructosamine and GA reflect blood glucose 
levels for the past 2-3 weeks (Rodriguez-Segade et al. 2011). Therefore both can be used 
for short term (2-3 weeks) glycaemic control (National Institute of Health 2010). However 
due to albumin and other plasma protein’s  greater susceptibility to glycation compared to 
intracellular proteins such as hemoglobin, the blood levels of fructosamines or GA exhibit a 
broader fluctuation than those of HbA1c, allowing an earlier detection of rapid changes in 
blood glucose levels (Rondeau & Bourdon 2011). Hence measurement of fructosamines 
and GA is regarded as an attractive alternative, especially in patients in whom the 
measurement of HbA1c may be biased or even unreliable or when quicker detection of 
changes in glycaemic control is needed, such as in pregnancy (Danese et al. 2015). 
 
Conditions linked to hypoproteinaemia such as pregnancy or malnutrition and also abnormal 
levels of  immunoglobulins (Ig), especially IgA are more likely to affect the concentration of 
fructosamines (Rodriguez-Segade et al. 1989). In brief, all clinical conditions affecting 
protein metabolism are more likely to influence the concentration of fructosamines. 
Furthermore diseases such as liver cirrhosis and hypothyroidism result in a prolonged half-
life of albumin leading to increased GA levels, whereas diseases such as nephrotic 
syndrome decrease the half-life of albumin leading to decreased levels of GA (Okada et al. 
2011) . Unlike HbA1c, fructosamines are not genetically influenced. This is supported by the 
findings in non-diabetic monozygotic and dizygotic twins study where it was shown that  
fructosamine levels were significantly correlated in these twins (Cohen et al. 2006). 
However, GA is a more preferred intermediate glycaemic marker compared to fructosamines 
due to reported higher specificity and accuracy (Danese et al. 2015).  
1.6.3. Advanced glycation end products (AGEs) 
The non-enzymatic glycation of proteins forms major intermediates (Schiff bases and 
Amadori products) which undergo a series of further, slower reactions and rearrangements 
leading to the formation of AGEs (Szwergold et al. 2002). Whilst AGEs are formed from 
chemical reactions with sugars, they can also be derived exogenously from tobacco (Nicholl 
& Bucala 1998) and certain foods, particularly those that are heated and browned (O’Brien 
et al. 1989). 
 
Stellenbosch University  https://scholar.sun.ac.za
18 
 
In the 1980s it was postulated that The Maillard reaction of proteins could be a factor in 
aging and in the development or worsening of diabetic complications, although the 
mechanism behind this was not clearly understood (Monnier & Cerami 1982). AGEs are 
irreversible and it was discovered that they induce aging by accumulating in stable and long 
lived extracellular proteins such as collagen (Meng et al. 1996), crystallins (Van Boekel & 
Hoenders 1992) and histones (Gugliucci & Bendayan 1995), consequently having 
detrimental effects on cell functioning  (Hirata et al. 1997) and contributing to diabetic 
complications and the development of neurodegenerative diseases (Vlassara, Bucala and 
Striker 1994; Brownlee 2001). It is believed that the interaction of AGEs with receptors for 
advanced glycation end products (RAGE) on cell surfaces could be the main pathogenic 
cause of diabetic complications. AGE bind to RAGE forming the AGE-RAGE complexes on 
plasma proteins, inducing changes in gene expression of cells such as endothelial cells, 
mesangial cells and macrophages forming modified plasma proteins, they also trigger 
downstream signaling and transcriptional pathways that results in oxidative stress, 
inflammation and release of reactive oxygen species (ROS) as illustrated in Figure 1.3 below 
(Rahbar 2005 ; Oliveira et al. 2013).  
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Figure 1.3. Increased production of AGE precursors and its pathologic consequences, 
adapted from (Brownlee 2001). Mechanisms by which intracellular production of AGE 
precursors damages vascular cells. Covalent modification of intracellular proteins by 
dicarbonyl AGE precursors alters several cellular functions. Modification of extracellular 
matrix proteins causes abnormal interactions with other matrix proteins and with integrins. 
Modification of plasma proteins by AGE precursors creates ligands that bind to AGE 
receptors, inducing changes in gene expression in endothelial cells, mesangial cells and 
macrophages. 
 
1.7. Diabetic complications 
DM and its complications are a major cause of morbidity and mortality worldwide (Adler et 
al. 2000). However, hyperglycaemia alone cannot completely explain these complications. 
The DCCT and UKPDS found that intensive glycaemic control dramatically reduced 
microvascular complications but did not prevent them (DCCT 1993; UKPDS 1998).  In 
diabetics the formation of AGEs is accelerated by persistent hyperglycaemia resulting in 
significant adduct accumulation on long-lived macromolecules (Monnier et al. 2005). 
Diabetic retinopathy is a progressive disorder that affects blood vessels of the retina and 
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AGEs have been implicated in the initiation and progression of this condition. It has been 
reported that the expression of RAGE is upregulated in DM and is predominantly localized 
to glia in the inner retina where they form AGE-RAGE complexes which often occur at higher 
levels in diabetics (Soulis et al. 1997). Approximately one third of diabetics globally develop 
some degree of diabetic retinopathy and it is the commonest cause of blindness and loss of 
vision (Yau et al. 2012). As a result of this vision impairment, poverty in affected families 
may be exacerbated due to loss of jobs resulting in lack of income.  
Ne -(carboxymethyl) lysine (CML) constitutes major AGE accumulated in the renal 
basement membrane in patients with diabetic nephropathy and associated with upregulation 
of RAGE on the podocytes cells located on the Bowman’s capsule (Tanji et al. 2000). These 
findings led to conclusions that AGE may also play a role in glomerular injury in acute 
inflammatory glomerulonephritis. Diabetic nephropathy is damage to kidneys caused by DM 
and characterized by persistent proteinuria > 300 mg/24 h and increased blood pressure. 
Diabetic nephropathy can result in end stage renal disease requiring dialysis or 
transplantation (Andersen et al. 1983).  
A study performed in diabetics with a history of foot neuropathic ulceration found that skin 
auto-fluorescence, which is assumed to reflect tissue AGE accumulation is increased during 
early stages of diabetic neuropathy and correlates with severity of nerve dysfunction and 
foot ulceration (Meerwaldt 2005). These findings support the importance of the clinical 
impact of AGE accumulation in diabetic neuropathy. Diabetic neuropathies present in 
several ways. The commonest form is a diffuse progressive polyneuropathy affecting mainly 
the feet and characterized by sensory impairment including burning and numbness which is 
difficult to treat potentially resulting in amputation of the lower limb (Flemmer & Vinik 2000). 
This makes foot problems potentially life threatening in diabetics. It has also been reported 
that foot ulceration leads to prolonged lengths of hospitalization and is a significant cause of 
morbidity in diabetics (Frykberg 1998). 
Macrovascular complications include atherosclerotic diseases such as the coronary artery 
disease, peripheral arterial disease and stroke (ADA 2006). Atherosclerosis is narrowing of 
arterial lumen in the peripheral or coronary vascular system resulting from chronic 
inflammation and injury to the arterial walls in response to accumulation of oxidized lipids. 
Atherosclerosis results in cardiovascular diseases (CVD) which accounts for approximately 
65% of all deaths in diabetics, with the major CVDs such as ischaemic heart disease and 
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stroke accounting for the greatest proportion of these deaths. In fact diabetics have been 
described as having a cardiovascular risk equivalent to someone who has already had a 
myocardial infarction (Whitely et al. 2005). The vascular complications of DM, including 
kidney diseases, myocardial infarction and stroke are increasing rapidly globally (Borch-
Johnsen 2007). AGEs are linked to atherosclerosis in multiple ways including enhancing 
endothelial dysfunction, elevating vascular low-density lipoprotein (LDL) levels by reducing 
LDL uptake and promoting plaque destabilization (Goh & Cooper 2008). In addition, 
experimental studies have demonstrated that AGEs are able to induce vascular calcification, 
with consequence in the aortic valve (Eupen et al. 2013). 
1.8. Glycation gap  
Among type 1 diabetics (Soros et al. 2010), type 2 diabetics (Rodriguez-Segade et al. 2011) 
and non-diabetics (Rohlfing et al. 2002)  considerable inter-individual differences in HbA1c 
levels that are not accounted for by corresponding variance in glycaemia levels. This 
imperfect relationship between HbA1c and glucose levels is due to various non-glycaemic 
determinants. Other studies have found that HbA1c is influenced by factors such as age, 
race, BMI, haemoglobinopathies, renal dysfunction, waist circumference, FPG, haematocrit, 
RBC count, current smoking status and alcohol consumption (Barth et al. 2008; Jansen et 
al. 2013). Factors that influence the life span of RBC affect HbA1c levels, with an increase 
in the mean age of RBC resulting in an increase in HbA1c levels and a decrease in mean 
age of RBC resulting in reduced HbA1c levels. This is supported by a Korean study which 
demonstrated that older individuals have higher HbA1C levels than younger individuals with 
similar glucose profiles (Lee et al. 2013). Patients with conditions such as iron deficiency 
anaemia which is one of the factors increasing RBC lifespan, have increased levels of 
HbA1c due to the altered lifespan of RBC (Adeoye et al. 2014). Patients with haemolytic 
anaemia have increased RBC turnover resulting in lower levels of HbA1c (Gram‐Hansen et 
al. 1990). Also, lower HbA1c levels have been observed in patients with chronic liver disease 
(Schnedl et al. 2005). Haemoglobinopathies such as HbAS (sickle cell trait) and HbC which 
are more common in SSA have been reported to interfere with measurement of HbA1c 
resulting in lower HbA1c levels (Bry et al. 2001). Patients with malaria infection have 
haematological effects such as anaemia due to lower levels of RBCs hence lower levels of 
HbA1c (Gallager et al., 2009). 
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HbA1c also exhibits racial and ethnic differences. A study on 4000 individuals participating 
in the Diabetes Prevention Program, reported that HbA1c levels were significantly higher in 
Blacks (6.2%), American Indian (6.1%), Asian (6.0%) and Hispanic (5.9%) subjects 
compared to Whites (5.8%) (Herman et al. 2007). This is in agreement with a study reporting 
that HbA1c levels are increased in Mexican Americans and Blacks compared to Whites 
(Cohen et al. 2008). A more recent study performed on 104 Blacks and 104 Whites aged 8 
years or older with type 1 DM demonstrated that HbA1c levels overestimate the mean 
glucose concentration in Blacks with mean HbA1c level being 9.1% in Blacks and 8.3% in 
Whites (Bergenstal et al. 2017).  
Yudkin et al referred to persons with HbA1c levels higher than expected for their plasma 
glucose levels as “high glycators” and those with lower than expected levels as “low 
glycators” (Yudkin et al. 1990). Discrepancies between HbA1c and fructosamine levels have 
also been reported in several studies (Macdonald et al. 2008  ; Hempe et al. 2002). Cohen 
et al then proposed measurement of the glycation gap to address this discrepancy 
encountered between HbA1c and average plasma glucose levels (Cohen et al. 2003). 
Glycation gap refers to the difference between measured  HbA1c and  the value predicted 
by regression of HbA1c on either fructosamine or GA (Cohen et al. 2003). Similarly McCarter 
proposed the measurement of haemoglobin glycation index (HGI) which differs from 
glycation gap in that it measures the difference between measured HbA1c and the value 
predicted by regression of HbA1c on mean blood glucose measured throughout the day 
(McCarter et al. 2004). 
 
Several studies have indicated that the glycation gap is consistent within individuals over 
time, therefore emphasizing the persistence of the underlying mechanism resulting in this 
variation encountered between HbA1c and other glycaemic measures (Rodriguez-Segade 
et al. 2015; Kim et al. 2016). These findings have led to assumption that the glycation gap 
could be a better glycaemic indicator than HbA1c. Furthermore, studies have reported on 
the association of the glycation gap with diabetic related complications.  Cohen et al and 
Rodriguez-Segade et al reported a positive correlation between the glycation gap and 
nephropathy (Cohen et al. 2003; Rodriguez-Segade et al. 2012). Additionally, a prospective 
cohort study performed on 3182 diabetics (Black, White and Asian) found that the glycation 
gap was significantly associated with retinopathy, nephropathy, macrovascular disease and 
mortality (Nayak et al. 2013). Hence, it was suggested that the glycation gap could improve 
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the quality of glycaemic control monitoring, especially in patients whose HbA1c levels do not 
truly reflect the mean blood glucose (Dziedzic et al. 2012). Similarly, studies on HGI reported 
that it is reproducible over time within an individual and it is positively correlated with diabetic 
related complications such as nephropathy and retinopathy (Hempe et al. 2015; McCarter 
et al. 2004). 
However, the glycation gap is also affected by factors such as creatinine levels, mean 
corpuscular hemoglobin concentration (MCHC) and metformin treatment (Zafon et al. 2013). 
Higher HbA1c levels relative to fructosamines have been described in patients treated with 
metformin implying that metformin facilitates glycation of haemoglobin hence overestimation 
of HbA1c levels (Zafon et al. 2013) . It has also been reported that the glycation gap is 
genetically determined and this is supported by the findings of the study performed in 
identical and non-identical twins which demonstrated that genetic factors contributed 69% 
of the glycation gap and only 31% was due to environmental factors (Cohen et al. 2006). 
This heritability of the glycation gap accounts for one third of the heritability of the HbA1c 
(Cohen et al. 2006). Since the glycation gap reflects the difference in HbA1c as determined 
in the intracellular compartments and the extracellular compartment of the RBC and these 
findings imply that there are genetic factors which influence the glycation reaction in the 
intracellular compartment but not in the extracellular compartment. Therefore, the glycation 
gap could be a useful predictor of factors other than glycaemia affecting HbA1c levels. 
Recently, it was suggested that the glycation gap should be used as an additional tool for 
glycometabolic monitoring especially for patients with conditions that may affect the 
reliability of the measurement of fructosamines and HbA1c (Paleari et al. 2016). 
1.9. Deglycation  
1.9.1. Discovery of Fructosamine 3 Kinase (FN3K) 
With growing evidence suggesting that the accumulation of AGE’s is associated with aging 
and the development of diabetic complications, the discovery of inhibitors of glycation has 
offered a potential therapeutic target for the prevention of diabetic complications related to 
non-enzymatic glycation of proteins. Fructosamine 3 kinase (FN3K) is a cellular repair 
enzyme involved in the deglycation process, a new form of protein repair (Avemaria et al. 
2015). FN3K was discovered during a study of cataracts performed in the lens of diabetic 
rat when a novel sugar phosphate called fructose-3-phosphate (Fru-3P) was identified in the 
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aging lens (Szwergold et al. 1990). Fru-3P is a potent glycating agent and a potential 
precursor of an alpha-dicarbo-nyl sugar, 3-deoxyglucosone (3DG) (Lal et al. 1995) The use 
of the tool, Phosphorus nuclear magnetic resonance (P-NMR) played a major role in the 
observation of the formation of Fru-3P first in lenses of diabetic animals then in erythrocytes 
of both control and diabetic subjects (Petersen et al. 1990). Although there was no known 
function of Fru-3P then, more investigations were performed on the erythrocytes extracts 
and it was demonstrated that an adenosine triphosphate (ATP) dependent kinase is involved 
in the production of Fru-3P. However, due to low affinity (Km ≥30 mM) of  FN3K for Fru-3P 
it was argued that the physiological substrate of FN3K was not fructose itself but compounds 
with closely related structure possibly fructosamine (Petersen et al. 1992).  
However, this kinase was poorly characterized until Delpierre and colleagues discovered 
that this enzyme can be inhibited by a synthetic fructosamine called 1-deoxy-1-
morphilinofructose (DMF) ( Delpierre et al. 2000). This discovery led to the identification, 
purification and cloning of human and mouse fructosamine kinases and alignment of these 
kinases showed 80% sequence identity. Human FN3K was identified as a 309-amino acid 
monomeric protein (Delpierre et al. 2000). This enzyme belongs to a family of 
aminoglycoside kinases and ethanolamine kinases (Delpierre et al. 2000).  
1.9.2. FN3K specificity, properties and role in deglycation 
Cloning of FN3K led to discovery that this kinase phosphorylates a wide variety of 
fructosamines. FN3K phosphorylates fructoselysine (FL) at their 3-hydroxyl group resulting 
in formation of fructoselysine 3 phosphate (FL3P) in tissue extracts (Szwergold et al. 1997). 
The close proximity of ketoamine group and phosphates in the FL3P makes it unstable, 
therefore it will readily decompose resulting in regeneration of lysine, 3-DG and inorganic 
phosphate as illustrated in Figure 1.4 below (Szwergold et al. 1997). FN3K is a deglycation 
and protein repair enzyme. FN3K phosphorylates fructosamine bound proteins leading to 
regeneration of lysine residues and preventing further reaction to AGEs, Figure 1.4 
(Szwergold et al. 1997).  However, deglycation is said to occur more rapidly on 
fructosamines bound to the side chains of lysine and slower on those bound to the side 
chains of valine due to their lack of accessibility. Therefore, the ability of FN3K to act on 
fructosamine is decreased as it is bound to α amino group of amino acids (Delpierre & 
Schaftingen 2003). Recently, a study performed on 67 subjects (age: 76±8 years) with an 
aortic valve stenosis, found that the use of ATP-dependent FN3K reduced the concentration 
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of fructosamine in the aortic valve resulting in increased flexibility of these valves (Cikomola 
et al. 2016). Hence FN3K potentially plays an important role as a deglycating enzyme 
especially in the control of diabetic complications in association with non-enzymatic 
glycation of proteins and supplementation of FN3K may be useful as a repair mechanism. 
 
 
 
Figure 1.4. Proposed role of FN3K as a catalyst in the decomposition of fructoselysine 
(FL). Adapted from (Szwergold et al., 2002). Phosphorylation of FL results in the formation 
of Fructoselysine-3-phosphat (FL3P) which is intrinsically unstable and decomposes 
spontaneously to lysine, inorganic phosphate and 3-deoxyglucosone, thereby regenerating 
an unmodified protein. 
 
Inhibition of FN3K using its competitive inhibitor DMF in intact erythrocytes and incubating 
them in glucose further substantiated its role in deglycation. The subsequent accumulation 
of HbA1c increased about twofold (Delpierre et al. 2002). Veiga-da-Cunha et al confirmed 
this and reported that the levels of haemoglobin-bound fructosamines was about 2, 5-fold 
higher in FN3K -/- mice than FN3K +/+ or FN3K +/- mice. Additionally, they found that 
cytosolic proteins were 1.5 to 1.8 fold more glycated in tissues highly susceptible to glycation 
such as liver, kidney, brain and skeletal muscle of FN3K-/- mice than those of FN3K +/+ 
mice (Veiga-da-Cunha et al. 2006). In summary, protein deglycation catalyzed by FN3K is 
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a process of restoring proteins to their original structure and function prior to the Maillard 
modification (Delpierre et al. 2002; Beisswenger et al. 2003).  
1.9.3. FN3K substrate and tissue distribution 
FN3K is present in mammals and birds but not in fishes, plants and bacteria. The activity of 
this enzyme is absent/low in erythrocytes of pigs and chickens due to low intracellular 
glucose whereas high activities are found in erythrocytes of species such as humans, mice 
and rats where the intra-erythrocyte glucose concentration is equal to that of the plasma 
(Delplanque et al. 2004). This enzyme is encoded by the FN3K gene located on 
chromosome 17q25 and contains six exons encoding 309 amino acids. The FN3K gene is 
ubiquitous, expressed in all tissues and  highly expressed in tissues susceptible to glycation 
such as kidney, peripheral nerves and heart  (Conner et al. 2004). The FN3K gene is also 
present in low protein turnover tissues such as lenses and erythrocytes (Lal et al. 1993). 
However it was found that highly basic glycated proteins such as histones and cytochrome-
c are the preferred substrates of FN3K because of its high affinity (Szwergold et al. 2001). 
The presence of this enzyme in many cells and tissues imply that it might be important for 
the functioning and survival of some cells.  
1.9.4. Variability of FN3K activity 
The activity of FN3K is stable with time in a single individual but varies from subject to subject 
in a four-fold range (Delpierrre et al. 2004). Delpierre et al performed a study in type 1 
diabetics and non-diabetics to ascertain whether changes in FN3K activity were associated 
with distinct alleles of the FN3K gene. They identified six single nucleotide polymorphisms 
(SNPS) in the FN3K gene and suggested that they might be associated with the enzyme 
activity (Delpierre et al. 2006). However, of these six SNPs, only two were reported to have 
a significant association with the FN3K activity. The CC of the G900C (rs1056534) in exon 
6 and the GG of the c.–385A/G (rs3859206) in the promoter region were associated with 
reduced FN3K activity measured in erythrocytes (Delpierre et al. 2006). In addition, Mohas 
et al further investigated one of the SNPs reported by Delpierre (rs1056534) in type 2 DM 
(859) and controls (265) and found that the C allele of G900C was associated with lower 
HbA1c concentration and that this polymorphism was associated with the onset of disease. 
With the CC allelic variant, type 2 DM was diagnosed at a later age than in case of GC or 
GG variants (p<0.05) (Mohás et al. 2010).   
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An Italian study performed on both type 1 and 2 diabetics also confirmed the presence of 
some FN3K variants previously reported by Delpierre and identified additional genetic 
variants (c.187 A/C, IVS4-9 delTTG), and two new mutations (c.559 C/T, c.716 A/G).  
However, only some variants were found to be related to higher HbA1c levels and this was 
not significant (Mosca et al. 2011). Škrha et al also demonstrated the association of SNP 
rs1056534 and rs3848403 of FN3K gene with  serum levels of RAGE in diabetics (Škrha et 
al. 2014). Subsequently, Tanhäuserová et al demonstrated that SNP rs1056534 of the FN3K 
gene was associated with the progression of diabetic nephropathy and cardiovascular 
morbidity and mortality (Tanhäuserová et al. 2014).  
In a White cohort of 70 diabetics (35 with type 1 and 35 with type 2) and 33 controls the 
promoter of the FN3K gene was analyzed and evaluated for the presence of the two 
polymorphisms, the c.–385A/G (rs3859206) and the c.–232A/T (rs2256339). Two additional 
new variants (c.–421C/T; c.–429delATCGGAG) were found in one patient with type 1 DM 
(Avemaria et al. 2015). A recent study performed in a cohort of African diabetics and controls 
examining the activity of FN3K also reported a significant correlation with HbA1c values and 
a unique significant association between FN3K activity and the glycation gap (Cikomola et 
al. 2016). Therefore, the presence of this polymorphism may affect the protective role of 
FN3K by either reducing or increasing the activity of the enzyme hence these genetic 
variants may have a major effect on the progression of DM.  
1.9.5. Other Repair Enzymes 
After the cDNA encoding FN3K was cloned, Collard et al realized that mammalian and bird 
genomes encode FN3K-related protein (FN3K-RP) that is homologous to FN3K sharing 
approximately 60% amino acid sequence identity (Collard et al. 2003). The gene encoding 
for FN3K-RP is located at position 8 Kb upstream of the FN3K gene on chromosome 
17q25.3 (Collard et al. 2003). The mammalian and bird FN3K-RP doesn’t phosphorylate 
fructosamines, it catalyzes the phosphorylation of low molecular mass and protein bound 
ketoamine such as ribulosamines and erythrulosamines and with lower affinity 
psicosamines, all substrates which FN3K also acts on (Collard et al. 2003; Delplanque et al. 
2004). However, these substrates cannot be found in nature hence there are no known 
substrates of FN3K-RP. Furthermore FN3K-RP phosphorylates proteins on their third 
carbon (C3) in the D-configuration (D-allose and D-ribose) unlike FN3K, which 
phosphorylates C3 either in the L- or the D-configuration (Collard et al. 2004; Delplanque et 
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al.2004). 
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Purpose of the study 
 
Hypothesis:  
We hypothesise that SNPs of the FN3K gene influence the levels of the glycation gap. 
 
Research Question: 
What are the effects of the FN3K SNP genotypes on the variability encountered between 
HbA1c and fructosamines as measured by the glycation gap? 
 
Aim: 
The aim of this study was to examine the role of FN3K genotypes on the variability 
encountered between HbA1c and fructosamine as measured by the glycation gap. 
 
Objectives: 
 To investigate the allelic variant of FN3K SNP rs1056534 and rs2256339 in normal, 
pre-diabetic and type 2 diabetics of mixed ancestry descent.  
 To assess the variability between HbA1c and fructosamines by determining the 
glycation gap within normal, pre-diabetic and type 2 diabetics of mixed ancestry 
descent. 
Problem statement: 
Type 2 DM is a growing global problem and a major cause of morbidity and mortality. IDF in 
2017 reported that approximately 425 million people globally were diabetic (IDF 2017). The 
prevalence of DM has been found to be very high in the mixed ancestry population of Bellville 
South, Western Cape South Africa (Erasmus et al. 2012). Furthermore, this population has 
also been reported to have high rates of obesity and metabolic syndrome, and a high risk of 
developing CVD (Matsha et al. 2012). Non-enzymatic glycation of proteins has been strongly 
related to the pathogenesis of chronic diabetic complications as well as degenerative 
changes occurring in the course of aging. The glycation gap which explains the variability 
between HbA1c and other measures of hyperglycaemia has been associated with the onset 
of diabetic related microvascular complications such as nephropathy (Nayak et al. 2013). 
However, evidence has shown that the glycation gap could be genetically determined, and 
this accounted for one third of the heritability of HbA1c which implies that there are genetic 
factors which influence the glycation reaction in the intracellular compartment but not in the 
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extracellular compartment (Cohen et al. 2006). The glycation process may be moderated by 
an enzymatic deglycation process thought to involve a deglycating enzyme FN3K which 
forms part of a protein repair system and/or cellular defence. However, subject to subject 
variations in the activity of FN3K enzyme in erythrocytes has been reported and could 
potentially affect the levels of HbA1c independently of differences in the blood glucose level. 
In addition, there are several SNP’s in the FN3K gene which are said to influence the activity 
of the deglycating enzyme (Delpierre et al. 2006). 
 
Rationale for the study: 
The glycation gap has been suggested to be a better indicator than HbA1C for assessing 
the risk of death and hospitalization in diabetic dialysis patients. Thus, determining the 
glycation gap in any individual may be of importance especially in helping with the 
identification of individuals who are at risk of developing diabetic complications. The role of 
FN3K in deglycation is considered as a potential intracellular protein repair method and this 
has given hope for future therapeutic possibilities for diabetic related complications. 
Furthermore, better understanding of the possible effect of FN3K genetic variants on the 
progression of the DM and its ability to prevent adverse diabetic outcomes such as 
microvascular and macrovascular complications, morbidity and mortality in the management 
of diabetic patients is needed. The increasing prevalence as well as the socioeconomic 
burden of DM and its complications in developing countries necessitates reliable diagnostic 
methods, measures of glycaemic monitoring and therapeutic approaches of preventing or 
inhibiting the development of diabetic related complications which is a major priority in 
diabetic research.  
 
Research outputs:  
This study will form the master’s research project for the student involved in this study. The 
abstract of this research article will be presented at national and international conferences 
and workshops. It will also be published in a peer-reviewed accredited journal. Hence it will 
be allow further knowledge about the effect of FN3K genotypes of glycation gap. This study 
will be a valuable contribution to the mixed ancestry community and globally. 
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Chapter 2: Methodology 
 
2.1. Study design 
This was an observational case control study in which mixed-ancestry diabetic and non-
diabetic subjects of the Bellville South community, Western Cape, South Africa were 
compared to identify the frequency of the allelic variants of FN3K. The association between 
FN3K genotypes and the glycation gap was determined in diabetic, pre-diabetic and 
normoglycaemic subjects. This study formed part of the large Bellville South study 
investigating the risk factors for CVDs (Matsha et al. 2012).    
2.2. Study setting  
This study was conducted in Bellville South, which is located within the northern suburbs of 
Cape Town, Western Cape, South Africa. The township was formed in the late 1950s and 
is mainly inhabited by mixed ancestry population (88 %) (Wit et al. 2010). According to the 
census report of 2011 it was estimated that 24,642 individuals, with about 54 % females and 
46 % males are resident in Bellville South (Western Cape Census, 2011). Afrikaans is the 
predominant language, although other languages such as English and Xhosa are also 
spoken. Most of the residents have lived in the community for over five years, while others 
have been there for their entire lives. Therefore, this community presents an ideal study 
setting to investigate the effects of FN3K genotypes on the glycation gap in type 2 DM and 
non-diabetic people due to the high crude prevalence of type 2 DM (28.2%) (Erasmus et al. 
2012). 
2.3. Sample size 
Sample size calculation 
The sample size needed for this study was calculated using the DM prevalence of 28.2% 
reported by Erasmus et al. (2012) for the Bellville South community.   
The formulae used was:  
n = z2 (pq)/e2 
Where: 
n = the sample size 
z = standard error associated with the chosen level of confidence (1.96) 
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p = estimated percent in the population 
q = 100-p 
e = acceptable sample error (5%) 
Calculation 
n = z2 (pq)/e2 
n = {1.962(28.2 * (100-28.2)}/52 
n = 311 
Therefore, sample size needed was a minimum 311 participants. However; we used more 
than 311 participants: higher than sample size calculated as we examined different 
subgroups 
2.4. Study population 
The enrolment of subjects for this case control study was performed between 2014 and 
2016. A total of 1988 subjects were recruited and gave informed consent.  Anthropometric 
measurements including body weight, height, waist and hip circumferences as well as blood 
pressure were taken. Blood samples were taken after an overnight fast as well as after a 2 
hour glucose tolerance test (OGTT).  
2.4.1. Inclusion criteria 
All mixed-ancestry participants (diabetic and non-diabetic) enrolled in the study on a 
voluntary basis and gave informed consent in a language of their choice. 
2.4.2. Exclusion criteria 
Participants who were pregnant, aged less than 20 years, those with acute and chronic 
conditions and also those who did not volunteer to participate in the study were excluded. 
2.5. Data collection 
2.5.1. Clinical data 
2.5.1.1. Clinical assessment  
 
Anthropometric measurement, blood pressure measurement and blood collection were 
obtained. Anthropometric measurements included body weight, body height and waist and 
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hip circumferences. All anthropometric measurements were performed three times and the 
average of these measurements used for the final analysis. 
2.5.1.1.1. Height  
 
The Omron Body Composition Monitor (BF511: Omron, Japan) was used to measure both 
height and weight of the participants. The stadiometer was used to measure body height to 
the nearest 0.1 centimetre (cm). The participant had to stand upright on the flat surface of 
the stadiometer without shoes (Tolonen et al., 2002). The head was then placed in the 
Frankfort plane with hands freely at the sides. The scapular and buttocks were placed as 
close to the vertical sliding metallic bar as possible to ensure accurate readings. The sliding 
metallic bar was then allowed to gently rest on the subject’s head. If the participant was taller 
than the investigator, the investigator stood on a platform to enable an accurate reading.  
2.5.1.1.2. Weight  
 
The Omron Body Composition Monitor (BF511: Omron, Japan) was used to measure 
participants’ weight in kilograms (kg). Participants were weighed in light clothing and 
barefooted. The weight of all participants, except wheelchair bound or those who were 
posturally impaired was measured. The participant would stand on the centre of the flat 
surface of the scale after it had been zeroed. Hands were placed on the sides and after 
ensuring that the subject’s weight was evenly distributed, the reading was taken (Tolonen 
et al.,2002). Readings less than 0.5 kg were rounded off to the nearest lower kilogram while 
those above 0.5 kg were rounded off to the nearest higher kilogram. The body mass index 
(BMI) was calculated by dividing the weight and height squared [weight/height2] (kg/m2).  
2.5.1.1.3. Waist circumference  
A non-elastic tape that had been inspected for calibrations and stretch was used to measure 
the waist circumference (WaistC) (cm). Subjects were asked to stand in an erect position 
with hands placed on their sides and with their feet and abdominal muscles relaxed. 
Measurements were taken with the investigator in front of the participant, and by placing the 
measuring tape around the natural waist (narrowest part of the torso as seen from the 
anterior view). For obese participants, the narrowest circumference between the ribs and 
the iliac crest was measured  (Tolonen et al., 2002).   
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2.5.1.1.4. Hip circumference  
The hip circumference (HipC) (cm) was measured at the maximal circumference over the 
buttocks. A non-elastic tape was also used for this measurement. The investigator would 
place the tape around the buttocks on the widest area over the horizontal 23 plane without 
pressing tightly against the skin, and then take the measurement (Tolonen et al., 2002). 
2.5.1.1.5. Blood pressure measurements  
 
Measurements used to assess the blood pressure were systolic blood pressure and diastolic 
blood pressure. Systolic blood pressure (SBP) refers to the highest arterial pressure as a 
result of the exertion of the blood upon the walls of the blood vessels (arteries) immediately 
after the pumping action of the left ventricle of the heart. Diastolic blood pressure, in contrast, 
refers to the lowest arterial blood pressure when the heart muscles contract after a systolic 
event (Pickering et al. 2005). Blood pressure is expressed as SBP over DBP and the units 
are millimetres of mercury (mm Hg) (Pickering et al. 2005). 
Blood pressure measurements were performed according to WHO guidelines (WHO, 1999). 
Blood pressure measurements were taken using an automatic digital blood pressure monitor 
(Omron M6 Comfort-preformed Cuff Blood Pressure Monitor, Omron). Blood pressure 
measurements were taken with the participant sitting quietly in a relaxed position. 
Participants were allowed to sit with their back supported on the chair backrest, while their 
arms were exposed and rested on the table at the same level as their heart. The correct 
adult cuff size was placed 2 cm above the elbow joint to ensure accurate readings (Pickering 
et al. 2005). Three readings, at one minute intervals, were taken and the lowest reading was 
chosen as the participant’s blood pressure.  
2.5.1.1.6. Blood collection 
 
Phlebotomy was conducted by trained nursing sisters.Participants were requested to fast 
overnight before the morning of blood collection. All blood samples were drawn in a sitting 
position. Six blood tubes were collected for each participant: three fasting and three 2-hour 
post OGTT bloods. Self-reported type 2 DM participants (confirmed by either medical 
records or medications) had only the fasting blood samples taken and no 2-hour bloods 
were drawn. The following fasting and 2-hour blood samples were collected: one grey 
capped-tube (sodium fluoride), one plain tube (no clotting factors) and one purple capped-
tube (EDTA). The grey top tubes were used to measure blood glucose concentrations, while 
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the plain top tubes were centrifuged to obtain serum for serological tests such as serum 
cotinine, insulin and lipid profile. The purple capped-tubes (whole blood) were used to 
measure HbA1c levels and for DNA extraction. Blood samples collected were transported 
daily in an ice-box for processing at an accredited pathology practice, PathCare Reference 
Laboratory (Cape Town, South Africa) for biochemical analysis of samples. 
2.5.1.2. The oral glucose tolerance test (OGTT)  
All participants, excluding the self-reported diabetic subjects (confirmed by either participant 
medical card record or drug use), underwent an OGTT. Subjects were asked to fast 
overnight where after the OGTT was conducted according to WHO guidelines (WHO 1999): 
i) investigators asked participants whether they had fasted, ii) collected fasting blood 
samples, iii) gave participants 75 grams of anhydrous glucose dissolved in 250 - 300 ml of 
water, which was drunk within 3 - 5 minutes, and the time recorded, iv) collected  second 
blood sample after 2 hours (2h-PG).  
2.5.2. Biochemical data 
Biochemical measurements: Plasma glucose concentrations were measured using the 
hexokinase method (Cobas 6000, Roche Diagnostics; Mannheim, Germany), HbA1c was 
measured using high performance liquid chromatography (HPLC)(Biorad Variant Turbo), 
Insulin was measured using a Paramagnetic particle assay (Chemiluminescence),  
Fructosamine was measured using a Colorimetric test nitro-blue-tetrazolium  (Roche Cobas 
c311), LDL-chol (mmol/L) was measured using  an Enzymatic Selective Protection –
Endpoint assay (Beckman AU), HDL-chol (mmol/L)  using an Enzymatic Immunoinhibition-
Endpoint assay (Beckman AU) and the triglycerides were estimated using a glycerol 
phosphate oxidase in the presence of peroxidase (GPO-POD) Endpoint assay (Beckman 
AU).  
 
2.5.2.1. Formulas used 
The glycation-gap: The glycation-gap was determined according to a formula described 
by Nayak et al. (2013): Glycation Gap = HbA1c - FHbA1c (Fructosamine derived glycated 
haemoglobin) 
FHbA1c = [(
fructosamine- mean fructosamine
SD fructosamine
) X SD HbA1c] + mean HbA1c 
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Obesity:  Obesity was classified using the BMI values as proposed by the WHO (WHO 
2004, updated 2016). The formulae used is body weight (kg) / (height (m)) 2 ((kg/m2)). 
The classification is then as follows: 
 Underweight: < 18.50 kg/m2 
 Normal range: 18.50 to 24.99 kg/m2 
 Overweight: ≥ 25.00 to 29.99 kg/m2 
 Obese: ≥ 30.00 kg/m2 
 
Diabetes: Participants were classified according to the revised WHO criteria (WHO 2016). 
Participants were categorized as DM, pre-diabetes (IGT and/or IFG) or normoglycaemia 
according to their history of DM, as well as their fasting, and 2-hour glucose concentrations. 
The glycaemic sub-groups were classified as follow: 
 DM: if FBG is ≥7.0 mmol/L or post 2HR BG ≥11.1 mmol/L 
 IGT: if FBG is <7.0 mmol/L and post 2HR BG is between ≥7.8 mmol/L and <11.1 
mmol/L 
 IFG: if FBG is between 6.1 and 6.9 mmol/L and if measured, post 2HR BG is <7.8 
mmol/L  
 
2.5.3. Genotyping 
2.5.3.1. DNA extraction 
Human genomic DNA was isolated from whole blood collected in EDTA blood tubes and 
stored at -20oC. DNA was extracted from 1 - 2 ml of blood using the simple, fast and cost 
efficient salt extraction method. After thawing the frozen blood samples, it was resuspended 
into five times volume (~5 - 10 ml) of lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM 
EDTA; pH 7.4) to lyse the blood cells. Thereafter, the tubes were vigorously vortexed for 
about 10 - 15 seconds and then placed on ice for 5 minutes. This step was repeated three 
times followed by centrifugation 1,500 rpm for 10 minutes using a Beckman General 
Purpose centrifuge (Beckman Coulter Inc., CA, USA). The supernatant was discarded and 
the pellets obtained were washed with 10 ml of phosphate buffered saline (PBS; 2.68 mM 
KCl, 136 mM NaCl, 1.47 mM KH2PO4, and 8.1 mM Na2HPO4, pH 7.4) and centrifuged at 
1,500 rpm for 10 minutes, twice. Thereafter 3 ml of nucleic lysis buffer (10 mM Tris, 400 mM 
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NaCl, 2 mM EDTA; pH 8.2) and 300 μl of 10 % (w/v) sodium dodecyl sulfate (SDS) was 
added and the pellet was dissolved by vortexing. Thirty microliters of 10 mg/ml proteinase 
K was added, mixed well, and the suspension was incubated overnight at 55 °C in the water 
bath to digest proteins. 
The following day, 1 ml of a saturated solution of 6 M NaCl was added and the tubes were 
vigorously vortexed followed by centrifugation at 2,500 rpm for 10 minutes. The supernatant 
was carefully transferred to a clean 15 mL polypropylene tube where the DNA was 
precipitated by adding two volumes (~ 9 ml) of 100 % ice cold ethanol. DNA is insoluble in 
ethanol and will thus form a string like precipitate which was taken out if sufficiently large or 
where DNA precipitate was small samples were centrifuged at 8,000 rpm for 30 minutes and 
the DNA pellet kept. 
The DNA pellet was washed with 1 ml of 70 % ethanol, the eppendorf tubes were centrifuged 
in a microcentrifuge (Beckman Coulter Inc., CA, USA) at 13,800 rpm for 30 minutes. The 
supernatant was discarded, and the DNA pellet was dried by inverting the tube on a paper 
towel and thereafter air dried for 15 minutes. The DNA pellet was dissolved in 100 - 200 μl 
of nuclease free water, depending on the size of the pellet. Tubes were placed overnight on 
a mixer to aid suspension of the pellet. The concentration and purity (A260/A280) of the 
DNA samples were measured by Nanodrop spectrophotometry (Nanodrop one C, Thermo 
Fisher Scientific, USA). An A260/A280 ratio between 1.8 and 2.2 was indicative of pure 
DNA. A lower ratio is suggestive of the presence of protein, phenol or other contaminants 
which absorb strongly at or near 280 nm and 230 nm, respectively. 
2.5.3.2. Real time Polymerase Chain Reaction (RT-PCR) SNP Genotyping. 
 
In the present study genotypes for FN3K SNP G900C (rs1056534) and c. -232A/T 
(rs2256339) polymorphisms were determined with the Applied Biosystems™ QuantStudio™ 
7 Flex Real-Time PCR System 96 well fast from Thermo Fisher Scientific. Taqman SNP 
Genotyping Assays (primers and reagents) designed by Thermo Fisher Scientifics were 
used to amplify and detect specific SNPs alleles in the purified genomic DNA samples. The 
following primers were used: TCGGGCGGGAGTACAGGAGCCCTTC (forward) and 
TTGGGCACCATGCGAAGGCTGCTCA (reverse) for SNP G900C and primers 
GGGATACCGGGTCCCTGCAGGGAGC (forward) and 
CAAGCCCCAGCGCGCCCGCGAAGAG (reverse) for SNP c. -232A/T were used. 
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The reaction mixture for a 96 well plate  was prepared as follows: Firstly, a master mix for 
96 samples were prepared in a 2ml Eppendorf tube, consisting of the Taqman SNP 
genotyping mix, assay primers and distilled water as illustrated in Table 2.1 below. Then 
using a multichannel pipette, 8 µl of the master mix was pipetted into each well of the 96 
well plate, then 2µl of the genomic DNA (5ng/mL) samples were added into their specific 
wells. Three negative controls (NTC’s) were included on each plate and 2 µl of distilled water 
were added in control wells instead of genomic DNA samples as illustrated in Table 2.2 
below. Upon completion of pipetting all the wells were inspected for uniformity of volume. 
An optical adhesive film was used to completely cover the wells of the reaction plate.  
Table 2.1. The reaction master mix used in PCR amplification 
Components Master Mix 96 well plate  
Volume per well Volume for 96 well plate 
Master mix 
 Taqman SNP 
genotyping mix 
 Taqman primer mix 
 Distilled water 
 
5 µl 
 
0.25 µl 
3.75 µl 
 
 
 
500 µl 
 
25 µl 
375 µl 
 
Table 2.2: Preparation of reaction for 96-well plate for PCR amplification 
Components                                             96 well plate 
                           Total Volume per well is 10 µl. 
93 wells for samples 3 wells for controls 
Master mix 
 
8 µl 8 µl 
DNA sample 2 µl Not added 
Distilled water Not added 2 µl 
 
The run conditions for the Taqman SNP Genotyping assays were optimized on the 
instrument. The following run conditions were optimal: 30 seconds pre-PCR read at 60.0oC, 
followed by hold stage at 95.0oC for 10 minutes, 40 cycles of PCR stage at 95.0oC for 15 
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seconds (Denature) and at 60.0oC for 1 minute (Anneal/extend), then the Post-Read stage 
at 60.0oC for 30 seconds. The reaction plate was loaded in the QuantStudio™ 7 flex Real 
time PCR System. After the run the results were obtained from the QuantStudio™ 7 Flex 
Real-Time PCR System software.  
Twelve of our genomic DNA samples were sent for sequencing at Inqaba Biotec (Cape 
Town) to confirm if the correct target SNPs were amplified. The sequencing protocol used 
were as follows: the PCR assay was done using the following conditions; EconoTaq PLUS 
2X Master Mix Catalog No. 30035 (10µl), gDNA (10-30ng/µl) (1µl), Forward primer (10µM) 
(1µl), Reverse primer (10µM) (1µl) and Nuclease free water Catalog No. E476 (7µl). After 
running the PCR, the PCR product was cleaned using ExoSAP protocol as follows; A 
Exo/SAP master mix was prepared by adding the following to a 0.6ml micro-centrifuge tube: 
Exonuclease I (NEB M0293) 20U/µl (50.0 µl), Shrimp Alkaline Phosphatase (NEB M0371) 
1U/µl (200.0 µl). Then the following reaction mixture was prepared: PCR Mixture (10.0µL) 
and Exo/SAP Mix (2.5µL). it was then mixed and incubated at 37°C for 30 min after which 
the reaction was stopped by heating the mixture at 95°C for 5 min. Sequencing was then 
done with the ABI V3.1 Big dye kit according to manufacturer’s instructions and the labelled 
products were then cleaned with the Zymo Seq clean-up kit. The cleaned products were 
injected on the ABI3500XL analysers with a 50cm array, using POP7 and the computer 
software program was used to read the results. 
2.6. Statistical analysis 
Data was analysed using a software program Statistica (Statsoft, http://www.statsoft.com). 
General characteristics of the study group were summarized as count and percentage for 
dichotomous traits, mean and standard deviation (SD) or median and 25th-75th percentiles 
(skewed data) for quantitative traits. SNPs were tested for departure from Hardy-Weindberg 
Equilibrium (HWE) expectation via a chi square goodness of fit test. One-way ANOVA was 
used to determine the mean, SD of the glycation gap in the normoglycaemic, pre-diabetic 
and diabetic sub-groups and the Bonferroni test was used to compare multiple groups of 
categorized parameters. Spearman Rank Order correlation was used to do correlation 
studies for non-parametrics (r and p). A P-value of < 0.05 was taken as statistically 
significant. 
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2.7. Ethical consideration 
Ethical approval for the larger study (CPUT/HW-REC 2015/H01) (2nd renewal) was granted 
by the Cape Peninsula University of Technology Faculty of Health and Wellness Sciences 
Research Ethics Committee and for the sub study (S16/06/100) Stellenbosch University 
Health Research Ethics Committee. Research was conducted according to the Code of 
Ethics of the World Medical Association (Declaration of Helsinki). Participants were given a 
written informed consent to sign after fully explaining procedures in the language of their 
choice.   
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Chapter 3: Results 
3.1. The general characteristics of the study population  
The general characteristics of the study population categorized by gender were summarized 
in Table 3.1. Age (years) was significantly higher in females than in males, mean ± SD for 
females were 50.3±14.8 and for males 47.4±15.8 (p=0.0022). Anthropometric 
measurements, including BMI (kg/m2), WaistC (cm) and the HipC (cm) were significantly 
higher in females than in males (all p<0.0001). Glycaemic measurements, including fasting 
blood glucose (mmol/L), 2-hour post OGTT glucose (2h-PG) (mmol/L), HbA1c (%), fasting 
insulin (mIU/L), 2-hours post OGTT insulin (2h- PI) (mIU/L) and the glucose/insulin ratio 
were all significantly higher in females than in males (All p<0.0001). There was no gender 
difference in fructosamine-S (µmol/L) levels (p=0.4114), but similar to the other glycaemic 
measures, the glycation-gap was also significantly higher in females than in males, mean ± 
SD for females was 0.18±0.89 and for males -0.24±0.83 (p<0.0001) (Figure 3.1). The lipids, 
including LDL-Chol (mmol/L), HDL-Chol (mmol/L) and Total-Chol (mmol/L) were significantly 
(all p<0.0001) and the Triglycerides-S (mmol/L) near-significantly (p=0.0904) higher in 
females than in males. The percentage of smokers was significantly higher in males than in 
females (p<0.0001). 
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Table 3.1. Characteristics of the study population categorized by gender  
 
 Total, N1412 Male, N339 Female, N1073  
     
 Mean ± SD Mean ± SD Mean ± SD p-value 
Age (years) 49.6±15.1 47.4±15.8 50.3±14.8 0.0022 
BMI (kg/m2) 29.3±8.0 24.5±6.3 30.8±7.9 <0.0001 
WaistC (cm) 92.9±16.9 86.3±16.1 94.9±16.7 <0.0001 
HipC (cm) 104.8±16.3 94.8±12.2 107.9±16.1 <0.0001 
WHR 0.89±0.08 0.91±0.09 0.88±0.08 <0.0001 
SBP (mmHg) 127.8±24.1 127.2±24.7 128.0±23.9 0.6030 
DBP (mmHg) 82.1±14.0 80.9±15.6 82.5±13.4 0.0747 
Pulse (bpm) 71.4±12.8 68.6±13.3 72.3±12.5 <0.0001 
Fasting Blood Glucose (mmol/L)  5.78±2.91 5.24±1.94 5.95±3.13 <0.0001 
2 Hours Post Glucose (mmol/L)  6.68±3.11 5.57±2.61 7.05±3.17 <0.0001 
HbA1c (%)  6.21±1.58 5.87±1.16 6.31±1.68 <0.0001 
Fasting Insulin (mIU/L)* 7.00 (4.40; 10.9) 4.85 (2.80; 8.50) 7.50 (5.00; 11.6) <0.0001 
2 Hours Post Insulin (mIU/L)* 39.6 (21.0; 72.5) 21.6 (9.8; 42.1) 47.7 (25.6; 79.7) <0.0001 
Glucose/Insulin ratio  1.01±0.93 1.31±1.10 0.92±0.85 <0.0001 
Fructosamine-S (µmol/L) 258.5±68.7 262.4±58.3 257.5±71.1 0.4114 
Glycation gap  0,10±0.90 -0.24±0.83 0.18±0.89 <0.0001 
Triglycerides-S (mmol/L)* 1.22 (0.87; 1.71) 1.13 (0.84; 1.66) 1.25 (0.89; 1.73) 0.0904 
LDL-Chol (mmol/L) 3.22±1.03 2.92±1.01 3.32±1.02 <0.0001 
HDL-Chol (mmol/L) 1.33±0.36 1.26±0.38 1.35±0.35 <0.0001 
Total-Chol (mmol/L) 5.18±1.17 4.82±1.16 5.30±1.16 <0.0001 
Chol/HDL ratio 4.11±1.21 4.06±1.38 4.13±1.15 0.3861 
Serum Cotinine (ng/mL) 135.8±158.9 155.1±151.2 129.7±160.8 0.0113 
Smokers, Yes, % (N) 48.6% (668/1374) 60.7% (201/331) 44.8% (467/1043) <0.0001 
Key: *: median and range (25Q; 75Q) 
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Figure 3.1. The glycation-gap was significantly higher in females than in males, mean ± 
SD respectively 0.18 ± 0.89 and -0.24±0.83 (p<0.0001) 
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3.2. The Hardy-Weinberg Equilibrium (HWE) results 
The FN3K SNP G900C (rs1056534) and SNP c. -232A/T (rs2256339) were tested for 
departure from HWE expectation via a chi square goodness of fit test. Results are 
summarized in Table 3.2. The table shows the allele and genotype distribution of SNP 
G900C investigated in the present study. SNP c. -232A/T deviated from Hardy Weinberg 
Equilibrium (HWE) in the overall sample (p=0.0004) and in normal controls (p=0.0012), 
whilst SNP G900C did not deviate in all groups (p>0.7281). Therefore, SNP c. -232A/T was 
left out for the rest of the statistical analysis. 
The genotype frequencies for SNP G900C in the glycemic sub-groups were as follows, GG: 
45.9 %, GC: 43.7 %, CC: 10.4 % in normal subjects; GG: 48.6 %, GC: 41.7 %, CC: 9.7% in 
pre diabetic subjects and GG: 41.7 %, GC: 46.5 %, CC: 11.8 % in the diabetic subjects. 
There were no significant differences in the SNP G900C genotype frequencies between the 
glycaemic sub-groups. 
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Table 3.2. Genotype distributions, minor allele frequencies  
 
  Normoglycaemia Prediabetes Diabetes Overall 
N 925 216 271 1412 
SNP G900C 
G/G, n (%) 425 (45.9) 105 (48.6) 113 (41.7) 643 (45.5) 
G/C, n (%) 404 (43.7) 90 (41.7) 126 (46.5) 620 (43.9) 
C/C, n (%) 96 (10.4) 21 (9.7) 32 (11.8) 149 (10.6) 
C, n (%) 596 (32.2) 132 (30.6) 190 (35.1) 918 (32.5) 
HWE (p-value) >0.999 0.7893 0.7281 0.9979 
     
SNP c. -232A/T 
T/T, n (%) 373 (40.3) 83 (38.4) 113 (41.7) 569 (40.3) 
T/A, n (%) 393 (42.5) 99 (45.8) 113 (41.7) 605 (42.8) 
A/A, n (%) 159 (17.2) 34 (15.7) 45 (16.6) 238 (16.9) 
A, n (%) 711 (38.4) 167 (38.7) 203 (37.5) 1081 (38.3) 
HWE (p-value) 0.0012 0.6214 0.0701 0.0004 
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3.3.  The general characteristics of the study population 
categorized by gender and SNP G900C genotypes. 
Clinical and biochemical features of the study population according to gender and genotypes 
of the G900C polymorphism of the FN3K gene were summarized in Table 3.3. There was a 
significant difference in the BMI (kg/m2) and Hip C (cm) in the genotype categories in 
females, p=0.0444 and p=0.0227 respectively, however this was not observed in males 
p=0.3801 and p=0.7804. The fasting blood glucose (mmol/L) was significantly increased 
across the GG, G/C and C/C genotypes in females, mean ± SD were; 5.74±2.71, 6.01±3.09 
and 6.52±4.52 respectively, p= 0.0433. The difference was not observed in males. The 
glycation gap significantly decreased  across the GG, G/C and C/C genotype variants in 
males, mean ± SD were -0.13±0.86, -0.25±0.72 and -0.80±1.04 respectively, p=0.0239 
(Figure 3.2) however the difference was not observed in females. The HbA1c level also 
decreased across the G/G, G/C and C/C genotype variants in males, however the difference 
was non-significant (p= 0.3009). 
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Table 3.3. The general characteristics of the study population categorized by gender and SNP G900C genotypes 
 
  SNP G900C genotypes, Females   SNP G900C genotypes, Males  
  G/G N475 G/C N477 C/C N121   G/G N168 G/C N143 C/C N28  
           
  Mean ± SD Mean ± SD Mean ± SD p-value  Mean ± SD Mean ± SD Mean ± SD p-value 
Age (years)  50.2±14.6 50.3±14.9 50.4±15.2� 0.9952  47.6±16.0 46.7±15.8 49.8±15.4 0.6143 
BMI (kg/m2)  31.1±7.8 30.9±8.1 29.1±7.4 0.0444  25.0±7.2 24.0±5.4 24.2±5.2 0.3801 
WaistC (cm)  95.8±17.0 94.7±16.2 92.6±17.0 0.1540  86.6±17.1 85.8±15.3 87.1±14.5 0.8737 
HipC (cm)  108.7±16.0 108.1±16.3 104.2±15.6 0.0227  94.3±13.6 95.1±10.5 95.8±11.8 0.7804 
WHR  0.88±0.08 0.88±0.08 0.89±0.08 0.4714  0.91±0.09 0.90±0.10 0.91±0.07 0.3239 
SPB (mmHg)  127.7±22.9 128.1±24.5 129.1±25.3 0.8423  126.3±24.0 127.6±25.0 131.0±27.9 0.6331 
DBP (mmHg)  82.4±13.6 82.6±13.4 82.0±13.3 0.8797  80.4±14.4 80.6±16.4 85.1±18.0 0.3248 
Pulse (bpm)  72.7±12.4 72.1±12.9 72.0±11.2 0.6982  68.4±12.7 69.0±14.0 67.5±13.8 0.8313 
Fasting Blood Glucose 
(mmol/L)  
 5.74±2.71 6.01±3.09 6.52±4.52 0.0433  5.30±2.17 5.16±1.71 5.29±1.59 0.8031 
2 HRs Post Glucose 
(mmol/L) 
 6.93±3.00 7.21±3.39 6.89±2.88 0.3742  5.45±2.30 5.60±2.76 6.03±3.47 0.5674 
HbA1c (%)  6.22±1.50 6.36±1.76 6.46±2.00 0.2568  5.96±1.31 5.79±1.02 5.71±0.73 0.3009 
Fasting Insulin (mIU/L)*   
5.35 (7.50; 
11.70) 
7.40 (4.75; 
11.85) 
7.60 (4.80; 
11.20) 
0.6232  
4.70 (2.80; 
8.20) 
4.80 (2.80; 
9.80) 
5.55 (2.90; 
9.15) 
0.8239 
2 HRs Post Insulin (mIU/L)*  
46.4 (25.2; 
80.3) 
47.5 (25.8; 
78.2) 
52.0 (27.3; 
90.5) 
0.6392  
21.5 (10.6; 
41.7) 
21.5 (9.8; 43.3) 23.8 (5.9; 53.6) 0.9985 
Glucose/Insulin ratio   0.86±0.71 0.94±0.83 1.04±1.29 0.0780  1.33±1.16 1.30±1.08 1.23±0.88 0.8929 
Fructosamine-S (µmol/L)  250.9±59.1 263.0±74.6 260.7±94.6 0.1100  263.8±63.1 258.5±50.8 280.2±74.4 0.4537 
Glycation gap   0.24±0.81 0.14±0.96 0.15±0.94 0.3735  -0.13±0.86 -0.25±0.72 -0.80±1.04 0.0239 
Triglycerides (mmol/L) *   
1.24 (0.89; 
1.73) 
1.26 (0.89; 
1.76) 
1.22 (0.86; 
1.63) 
0.6818  
1.13 (0.87; 
1.64) 
1.09 (0.79; 
1.65) 
1.29 (0.87; 
1.99) 
0.2936 
LDL-Chol (mmol/L)  3.33±1.02 3.34±1.06 3.19±0.85 0.3765  2.97±0.99 2.86±1.04 2.92±0.94 0.6399 
HDL-Chol (mmol/L)  1.35±0.38 1.35±0.32 1.35±0.34 0.9744  1.28±0.37 1.22±0.40 1.30±0.37 0.2927 
Total-Chol (mmol/L)  5.33±1.18 5.31±1.18 5.16±0.94 0.3687  4.89±1.14 4.72±1.17 4.85±1.16 0.4340 
Chol/HDL ratio  4.17±1.18 4.11±1.12 4.04±1.11 0.5202  4.02±1.40 4.13±1.38 3.94±1.23 0.7082 
Serum Cotinine (ng/mL)  132.8±159.3 122.4±159.5 145.5±171.5 0.3225  152.8±150.5 151.1±146.7 189.8±178.9 0.4595 
Smokers, Yes, % (N)  
217/464 
(46.8%)  
193/460 
(42.0%) 
57/119 (47.9%) 0.2602  96/161 (59.6%) 88/143 (61.5%) 17/27 (63.0%) 0.9150 
Key:  
*: median and range (25Q; 75Q) 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
48 
 
 
 Mean 
 Mean±SD 
 Mean±1.96*SD 
G/G G/C C/C
FN3K(rs1056534)
-3.5
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
G
ly
c
a
ti
o
n
-g
a
p
 
Figure 3.2. The glycation-gap showed a significant decrease through the FN3K SNP 
G900C (rs1056534) genotypes in males, mean ± SD in genotype G/G -0.13±0.86, in 
genotype G/C -0.25±0.72 and in genotype C/C -0.80±1.04 (p=0.0239). (Results were not 
significant in females). 
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3.4. Characteristics of the total study population categorized 
according to the Glycation-gap and glycaemic sub-groups. 
Characteristics of the total study population categorized according to the glycation-gap and 
glycaemic sub-groups were summarized in Table 3.4. There was no significant difference in 
genotype frequencies (%) observed in the glycation-gap categories (Negative, Neutral and 
Positive) in normal, pre-diabetic and diabetic subjects (p=0.4318, p=0.7950 and p=0.1222 
respectively). There was a significant difference in age (years) across the glycation gap 
categories in diabetic subjects p=0.0300 however no difference was observed in normal and 
pre-diabetic subjects. There was a significant increase in the BMI (kg/m2) (all p< 0.02) as 
well as the WaistC (cm) (all p<0.04) across the glycation-gap categories in normal, pre-
diabetic and diabetic subjects, while the HipC (cm) increased significantly across the 
glycation gap categories in normal and pre-diabetic subjects only (all p<0.03).  
The glycaemic measures including fasting blood glucose (mmol/L), 2h-PG (mmol/L), HbA1c 
(%), fasting insulin (mIU/L), 2h-PI (mIU/L) increased significantly across the glycation gap 
categories in normal subjects (all p<0.02). HbA1c (%) and fasting insulin (mIU/L) increased 
in the pre-diabetic group from the neutral to the positive glycation gap categories (all p<0.04) 
(the negative glycation gap category had too few numbers for meaningful statistical 
analysis). The fasting blood glucose (mmol/L), 2h-PG (mmol/L), HbA1c (%), fasting insulin 
(mIU/L), 2h-PI (mIU/L) increased significantly from the neutral to the positive glycation gap 
categories (all p<0.04) (the negative glycation gap category had too few numbers for 
meaningful statistical analysis).  Fructosamine (µmol/L) decreased significantly across the 
glycation-gap categories in normal, pre-diabetic and diabetic subjects (all p<0.0001). 
Triglycerides (mmol/L) significantly increased across the glycation-gap categories in all 
glycaemic groups (all p<0.04). The HDL-Chol (mmol/L) significantly decreased across the 
glycation-gap categories in normal subjects (p=0.0004) however no difference was 
observed in pre-diabetic and diabetic subjects. 
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Table 3.4. Characteristics of the total study population categorized according to the Glycation-gap and glycaemic sub-groups 
 
 Categorized G-gap   Categorized G-gap   Categorized G-gap  
 Normoglycaemic subjects, N501   Pre-DM subjects, N141   DM* subjects, N184  
G-Gap categorization  Negative Neutral Positive   
Negative*
* 
Neutral Positive   Negative**  Neutral Positive  
 Mean ± SD p-value  Mean ± SD p-value  Mean ± SD p-value 
N (%) 
42/501 
(8.38%) 
429/501 
(85.63%) 
30/501 
(5.99%) 
  
5/141 
(3.55%) 
119/141 
(84.40%
) 
17/141 
(12.06%) 
  
20/184 
(10.87%) 
115/18
4 
(62.50
%) 
49/184 
(26.63
%) 
 
               
SNP G900C genotypes               
G/G N (%) 
18/42 
(42.9%) 
184/429 
(42.9%) 
12/30 
(40.0%) 
  
2/5 
(40.0%) 
61/119 
(51.3%) 
8/17 
(47.1%) 
  
4/20 
(20.0%) 
50/115 
(43.5%) 
20/49 
(40.8%) 
 
G/C N (%) 
23/42 
(54.8%) 
196/429 
(45.7%) 
15/30 
(50.0%) 
  
3/5 
(60.0%) 
46/119 
(38.7%) 
8/17 
(47.1%) 
  
11/20 
(55.0%) 
56/115 
(48.7%) 
23/49 
(46.9%) 
 
C/C N (%) 
1/42 
(2.4%) 
49/429 
(11.4%) 
3/30 
(10.0%) 
  
0/5 
(0.0%) 
12/119 
(10.1%) 
1/17 
(5.9%) 
  
5/20 
(25.0%) 
9/115 
(7.8%) 
6/49 
(12.2%) 
 
FN3K(rs1056534) 
genotypes: Overall P-
value 
   0.4318     0.7950     0.1222 
               
Age (years) 
46.8±15.
6 
48.1±14.
5 
48.0±11.
2 
0.8531  60.6±15.1 
56.3±14
.1 
55.0±9.3 0.7220  62.0±13.3 
59.7±1
0.8 
55.4±10
.3 
0.0300 
BMI (kg/m2)  24.3±5.0 29.2±7.9 33.6±9.4 <0.0001  25.8±5.2 
31.8±8.
2 
36.3±5.3 0.0174  29.2±7.0 
32.6±7.
0 
34.5±6.
8 
0.0170 
WaistC (cm) 
82.8±12.
1 
93.5±16.
2 
104.5±1
8.5 
<0.0001  91.5±13.0 
100.0±1
5.4 
108.6±1
3.8 
0.0373  96.2±12.2 
102.5±
12.2 
108.2±1
3.6 
0.0010 
HipC (cm) 
99.4±11.
1 
107.4±1
5.1 
115.1±2
0.3 
0.0001  98.0±10.5 
111.1±1
6.1 
118.5±1
1.2 
0.0278  105.3±13.6 
111.0±
13.8 
114.1±1
3.4 
0.0531 
WHR 
0.83±0.0
6 
0.87±0.0
8 
0.91±0.0
9 
0.0002  0.93±0.07 
0.90±0.
07 
0.92±0.0
7 
0.5047  0.92±0.09 
0.93±0.
09 
0.95±0.
07 
0.2053 
SPB (mmHg) 
117.9±2
1.3 
123.6±2
1.9 
125.7±2
2.4 
0.2231  
134.4±28.
4 
129.6±2
1.6 
128.5±1
8.5 
0.8649  143.9±35.5 
134.0±
19.2 
136.0±2
4.7 
0.2054 
DBP (mmHg) 
80.6±12.
3 
81.3±13.
2 
82.1±16.
1 
0.9046  85.0±7.2 
82.0±12
.3 
81.1±12.
0 
0.8170  87.9±12.0 
83.5±1
1.5 
85.2±12
.7 
0.2618 
Pulse (bpm) 
70.6±10.
6 
69.7±12.
1 
74.1±13.
2 
0.1464  64.8±8.5 
72.1±13
.4 
77.5±11.
5 
0.1152  82.5±17.9 
73.8±1
3.2 
81.5±14
.7 
0.0013 
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Fasting Blood Glucose 
(mmol/L) 
4.79±0.4
2 
4.75±0.5
0 
5.02±0.4
9 
0.0146  5.28±0.68 
5.27±0.
62 
5.41±0.6
7 
0.6980  12.03±5.16 
8.41±3.
96 
10.31±4
.82 
0.0006 
2 HRs Post Glucose 
(mmol/L) 
5.59±1.2
1 
5.55±1.3
2 
6.38±1.0
9 
0.0032  8.58±0.82 
8.88±1.
10 
8.99±1.3
8 
0.7742  17.76±3.37 
12.98±
2.89 
15.93±3
.10 
0.0005 
HbA1c (%) 
5.24±0.3
9 
5.61±0.3
9 
6.35±0.3
7 
<0.0001  5.24±0.55 
5.92±0.
44 
6.61±0.3
2 
<0.000
1 
 8.89±2.21 
7.84±2.
08 
9.63±2.
32 
<0.000
1 
Fasting Insulin (mIU/L)*** 
4.85 
(3.60; 
7.50) 
6.70 
(4.30; 
9.60) 
9.20 
(5.90; 
16.20) 
0.0002  
10.10 
(6.80; 
12.70) 
9.00 
(5.60; 
14.40) 
12.60 
(8.60; 
19.20) 
0.0401  
7.85 (5.60; 
11.15) 
9.40 
(5.80; 
16.70) 
13.90 
(9.25; 
20.30) 
0.0026 
2 HRs Post Insulin 
(mIU/L)*** 
31.8 
(13.2; 
52.4) 
36.1 
(20.0; 
67.0) 
62.8 
(39.1; 
96.4) 
0.0018  
105.8 
(72.1; 
123.4) 
78.4 
(52.5; 
134.8) 
84.6 
(43.7; 
131.9) 
0.9935  
31.1 (30.6; 
40.5) 
67.7 
(39.4; 
95.7) 
77.6 
(72.4; 
99.2) 
0.0355 
Glucose/Insulin ratio  
1.14±0.6
9 
0.88±0.6
4 
0.65±0.4
8 
0.0055  1.00±1.13 
0.80±0.
67 
0.45±0.2
5 
0.881  1.86±1.67 
1.14±1.
15 
1.22±2.
01 
0.1359 
Fructosamine (µmol/L) 
275.3±2
2.3 
232.6±2
0.0 
208.0±1
7.4 
<0.0001  
269.1±20.
5 
240.6±2
0.7 
213.9±1
3.6 
<0.000
1 
 
459.5±126.
2 
323.8±
93.3 
325.2±8
9.7 
<0.000
1 
Glycation gap 
-
1.35±0.3
6 
-
0.01±0.5
2 
1.30±0.2
6 
<0.0001  
-
1.21±0.12 
0.12±0.
50 
1.42±0.3
0 
<0.000
1 
 -1.94±1.11 
0.13±0.
52 
1.89±0.
90 
<0.000
1 
Triglycerides (mmol/L)***  
0.92 
(0.68; 
1.29) 
1.09 
(0.81; 
1.56) 
1.33 
(0.83; 
1.88) 
0.0214  
1.12 
(0.74; 
1.58) 
1.35 
(1.03; 
1.77) 
1.99  
(1.34; 
2.59) 
0.0376  
1.56 (1.31; 
2.07) 
1.49 
(1.12; 
2.17) 
1.85 
(1.49; 
3.00) 
0.0077 
LDL-Chol (mmol/L) 
3.06±1.1
9 
3.24±1.0
2 
3.08±0.7
6 
0.4276  3.04±0.85 
3.55±0.
95 
3.39±0.7
7 
0.4172  3.77±1.00 
3.42±1.
05 
3.34±0.
91 
0.2717 
HDL-Chol (mmol/L) 
1.47±0.3
6 
1.30±0.3
2 
1.17±0.3
3 
0.0004  1.24±0.36 
1.30±0.
31 
1.28±0.2
4 
0.8936  1.26±0.29 
1.24±0.
34 
1.17±0.
27 
0.3553 
Total-Chol (mmol/L) 
5.09±1.2
9 
5.19±1.1
6 
4.95±0.8
4 
0.4977  4.88±0.94 
5.54±1.
08 
5.39±1.0
2 
0.3657  5.84±1.25 
5.35±1.
18 
5.33±1.
05 
0.1952 
Chol/HDL ratio 
3.61±1.0
7 
4.16±1.1
2 
4.61±1.5
3 
0.0009  4.22±1.67 
4.45±1.
13 
4.31±0.9
5 
0.8061  4.79±1.16 
4.52±1.
30 
4.70±1.
08 
0.5513 
Serum Cotinine (ng/mL) 
98.3±14
5.1 
143.1±1
61.4 
157.7±1
79.9 
0.1898  
79.4±108.
0 
117.7±1
62.5 
157.2±1
38.4 
0.5281  45.0±89.0 
92.1±1
54.7 
82.7±14
8.5 
0.4194 
Smokers, Yes, % (N) 
14/42 
(33.3%) 
208/427 
(48.7%) 
16/30 
(53.3%) 
0.1332  
2/5 
(40.0%) 
45/119 
(37.8%) 
10/17 
(58.8%) 
0.2559  
4/20 
(20.0%) 
28/115 
(24.3%) 
13/49 
(26.5%) 
0.8480 
Key: 
DM*: Screen-detected and known DM combined 
**: Numbers too low for meaningful statistical analysis 
***: Median and range (25Q; 75Q) 
 
 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
52 
 
3.5. Correlation analysis. 
Correlation between the general characteristics of the study population and the Glycation-gap, 
categorized by gender are summarized in Table 3.5. The glycation-gap is positively correlated with 
the BMI in the total group, males and females; r=0.3694, r=0.1973 and r=0.3428 respectively (all p 
<0.01) (Total group, Figure 3.3). Furthermore, the glycation-gap was positively correlated with Waist 
(cm), Hip (cm) and WHR in all groups, with the strongest correlations in the total and female groups. 
The glycation-gap is further positively correlated with fasting blood glucose (mmol/L), 2h-PG 
(mmol/L), fasting insulin (mIU/L) and 2h- PI (mIU/L) in the total group as well as in females (All 
<0.0001). In males the positive correlation was with fasting insulin (mIU/L) only (p<0.0001). 
The glycation-gap was positively correlated with triglycerides (mmol/L) in the total group and 
females r=0.2540 and r=0.3063 respectively (all p <0.0001). In contrast, the glycation-gap was 
negatively correlated with HDL-Chol (mmol/L) in the total group, males and females; r=-0.2031, 
p<0.0001; r=-0.1696, p=0.0294 and r=-0.2670, p <0.0001 respectively. 
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Table 3.5. Correlation between the general characteristics of the study population and the 
Glycation-gap, categorized by gender 
 
Glycation-gap Total, N826 Males, N167 Females, N659 
 r p-value r p-value r p-value 
       
Age (years) 0.0280 0.4223 -0.0419 0.5913 0.0566 0.1466 
BMI (kg/m2)  0.3694 <0.0001 0.1973 0.0111 0.3428 <0.0001 
WaistC (cm) 0.3749 <0.0001 0.2016 0.0092 0.3765 <0.0001 
HipC (cm) 0.3151 <0.0001 0.1748 0.0243 0.2696 <0.0001 
WHR 0.2423 <0.0001 0.1978 0.0106 0.3072 <0.0001 
SPB (mmHg) 0.0914 0.0086 -0.0578 0.4580 0.1449 0.0002 
DBP (mmHg) 0.0322 0.3555 -0.1403 0.0706 0.0720 0.0647 
Pulse 0.1747 <0.0001 0.0762 0.3276 0.1715 <0.0001 
Fasting Blood Glucose (mmol/L) 0.1981 <0.0001 0.0535 0.4923 0.2159 <0.0001 
2 Hours Post Glucose (mmol/L) 0.1948 <0.0001 -0.0444 0.6053 0.2147 <0.0001 
HbA1c (%) 0.5128 <0.0001 0.4453 <0.0001 0.5307 <0.0001 
Fasting Insulin (mIU/L)  0.3368 <0.0001 0.2093 0.0070 0.3241 <0.0001 
2 Hours Post Insulin (mIU/L) 0.2240 <0.0001 0.0560 0.5126 0.2045 <0.0001 
Glucose/Insulin ratio  -0.2753 <0.0001 -0.2315 0.0031 -0.2420 <0.0001 
Fructosamine-S (µmol/L) -0.4156 <0.0001 -0.4699 <0.0001 -0.3858 <0.0001 
Triglycerides (mmol/L)  0.2540 <0.0001 0.0245 0.7529 0.3063 <0.0001 
LDL-Chol (mmol/L) 0.0502 0.1505 -0.0227 0.7717 0.0470 0.2291 
HDL-Chol (mmol/L) -0.2031 <0.0001 -0.1696 0.0294 -0.2670 <0.0001 
Total-Chol (mmol/L) 0.0229 0.5119 -0.0369 0.6355 0.0089 0.8191 
Chol/HDL ratio 0.2011 <0.0001 0.1103 0.1584 0.2403 <0.0001 
Serum Cotinine (ng/mL) 0.0556 0.1111 0.0934 0.2297 0.0914 0.0191 
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Figure 3.3. The glycation-gap showed a significant positive correlation with the BMI (kg/m2) in the 
total group of subjects, r=0.3694; p<0.0001. (Similar results were shown in the male and female 
groups) 
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Chapter 4: Discussion 
4.1.   Introduction 
In this study, we investigated whether the genotypes of the FN3K gene had an effect on the 
variability encountered between HbA1c and fructosamine as measured by the glycation gap. Our 
results found that the glycation gap differed significantly across the genotypes of the FN3K SNP 
G900C. 
The IDF estimated that 425 million people (20-79 years) around the world had DM in 2017 and this 
number is projected to increase to 629 million by 2045. Furthermore, it was reported that 4.0 million 
people aged between 20 and 79 years died from DM in 2017 with the highest proportion (0.23 
million) of death occurring in the African region (IDF 2017). Non-enzymatic glycation of proteins has 
been implicated in the development of diabetic complications (Stitt et al. 2010). These proteins, 
such as HbA1c, fructosamine and glycated albumin may be useful in monitoring DM control and 
treatment, and recently HbA1c was also recommended for the diagnosis of DM (WHO 2011). HbA1c 
is a clinically relevant glycoprotein as it reflects the average plasma glucose for the past 2 - 3 months 
(Jeppsson et al. 2002). However, despite the reliability and standardization of HbA1c assays, 
several studies have reported inter-individual variations in the glycation of haemoglobin which may 
be due to factors other than glycaemia in type 1 DM (Cohen et al. 2003), type 2 DM (Rodriguez-
Segade et al. 2011) and in non-diabetic subjects (Yudkin et al. 1990). Fructosamine reflects the 
average plasma glucose for a shorter period than HbA1c and may be more readily influenced by 
short-term changes in blood glucose but its concentration in plasma is much more stable than that 
of glucose itself. Fructosamine level can also be influenced by non-glycaemic factors such as 
clinical conditions that affect protein metabolism (Schleicher et al. 1993) and pathologic conditions 
linked to hypoproteinemia (Rodriguez-Segade et al. 1989). 
Therefore, Cohen et al described the glycation gap which was used to study non-glycaemic factors 
which influence the glycation of haemoglobin (Cohen et al. 2003). Recent studies have found that 
the glycation gap is consistent over time within individuals (Nayak et al. 2011; Rodriguez-Segade 
et al. 2011) and is associated with diabetic complications as well as morbidity and mortality (Cohen 
et al. 2003; Rodriguez-Segade et al. 2011; Nayak et al. 2013). Therefore, determination of the 
glycation gap may be important to identify those who are at risk of developing diabetic complications 
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and also for therapeutic decisions. Recent identification of an enzyme FN3K as a part of a protein 
repair system opposing to the consequences of hyperglycaemia was of great interest (Delpierre et 
al. 2000). This enzyme catalyses the deglycation reaction which reverses the glycation of proteins 
thereby alleviating cellular damage due to accumulation of glycated proteins and protecting from 
diabetic complications (Szwergold et al. 2002). However, animal model studies have demonstrated 
that there is variation in the activity of FN3K enzyme between subjects (Veiga-da-cunha et al. 2006). 
Delpierre et al found that this variability in enzyme activity was associated with genetic 
polymorphisms in the FN3K gene (Delpierre et al. 2006). Recently Dunmore et al found that the 
variation in the glycation of proteins as measured by the glycation gap may be associated with 
differences in FN3K activity (Dunmore et al. 2018).  
Therefore, in the present study we investigated the effects of the FN3K SNP genotypes on the 
glycation gap. We analysed two FN3K SNPs G900C (rs1056534) and c. -232A/T (rs2256534) 
located on exon 6 and the promoter region of the FN3K respectively in a total of 1412 subjects (925 
normal, 216 pre-diabetic and 271 type 2 DM) aged ≥ 20 years. Out of the six SNPs of the FN3K 
described for the first time by Delpierre et al (Delpierre et al. 2006), we chose these two SNPs 
because they were  previously reported to be associated with FN3K activity and levels of HbA1c 
(Mohás et al. 2010; Mosca et al. 2011). The genotypes TT of SNP c. -232A/T and CC of SNP 
G900C have been associated with increased activity of FN3K enzyme (Delpierre et al. 2006). 
However, in our study the polymorphism c.-232A/T didn’t follow the Hardy-Weinberg Equilibrium 
and was therefore excluded from further analysis. The polymorphism G900C followed the Hardy-
Weinberg Equilibrium and was therefore further evaluated. We found no significance difference in 
the genotype frequencies of G900C between the glycaemic groups (normal, pre-diabetic and type 
2 DM), this is similar to the findings of Mohas et al who observed no significant differences in the 
genotype frequencies of SNP G900C between the type 2 diabetics and controls (Mohás et al. 2010). 
Delpierre et al also reported that the allele frequency was not significantly different between 
diabetics and controls (Delpierre et al. 2006). However, in our study the glycation gap levels were 
significantly higher in females compared to males (p<0.0001), the large number of females as 
compared to males and some confounders may partially have caused this difference.  
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4.2. FN3K genotypes and the glycation gap 
According to our knowledge this is the first study to establish the role of FN3K genotypes on the 
glycation gap globally. Our research question was whether the glycation gap is indeed affected by 
the genotypes of the FN3K and this was supported by our results. We found a significant decrease 
in the glycation gap across the G900C genotypes (GG, GC and CC), with the lowest level in the CC 
genotype (P=0.0239). Similarly, the concentration of HbA1c decreased across the G900C 
genotypes but this difference was not statistically significant (P=0.3009). However, these findings 
were only observed in males. We postulate that this might be due to the fact that in our population 
the females were obese (BMI 30.8±7.9) whereas the males were normal weight (BMI 24.5±6.3). In 
our study the glycation gap was significantly positively correlated with BMI, waist and hip 
circumference. The positive glycation gap subgroup had significantly higher BMI, waist and hip 
circumference compared to the neutral and negative glycation gap groups across all glycaemic 
groups.  
This is in agreement with the results of a study performed by Dunmore et al who analysed 148 
White type 2 diabetics with a mean age of 61.3 years and identified two glycation gap groups that 
were distinctly dichotomised with a consistently positive (67) or negative glycation gap (81) (> +0.5 
% or > -0.5 % HbA1c) and the glycation gap was calculated using the same formula as the one 
used in our study. They found that the negative glycation gap group had lower BMI levels compared 
to the positive glycation group in type 2 diabetics, mean +/- SD (30.2±5.2) and (35.4±6.7) p<0.001 
respectively (Dunmore et al. 2018). Similarly, Nayak et al analysed 3182 White, Asian and Black 
type 2 diabetics (≥18 years of age) and found that the glycation gap significantly positively correlated 
with BMI (Nayak et al. 2013). 
A recent retrospective cohort study was performed in 105 Korean subjects (mean age of 54.5) with 
type 2 DM. They calculated the glycation gap using the method described by Cohen et al (2003) 
where FHbA1c was derived from HbA1c-Fructosamine regression equation, which is different from 
the formula used in our study which was described by Nayak et al (2013). In this formula FHba1c 
was derived from simultaneously measured fructosamine standardized to the HbA1c distribution. 
However, instead of fructosamine they determined glycated albumin and the glycation gap was 
defined as the difference between the measured HbA1c level and that predicted from the glycated 
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albumin level, as calculated using the HbA1c-glycated albumin regression equation. They 
demonstrated that BMI, visceral fat area and abdominal subcutaneous fat were all significantly 
positively associated with the glycation gap (Kim et al. 2016). All these formulae found similar results 
to what was obtained in our study. However, to our knowledge, our study is the first to examine 
FN3K SNPs. Therefore, since the negative glycation gap implies that there is less glycation of 
haemoglobin than expected and positive glycation gap implies that there is more glycation of 
haemoglobin than expected, it may be postulated from these findings that individuals with higher 
BMI have higher rates of glycation and this may be expected as obesity is considered to be a risk 
factor for the development of type 2 DM (Motala et al. 2003). However, since in our study the males 
were normal weight we can postulate that the effect of the SNP G900C genotypes on the glycation 
gap was independent of obesity. Therefore it can be postulated that the glycation gap is influenced 
by genetic factors and this supports the findings of the monozygotic and dizygotic female twins 
study (40 and 46 pairs respectively) which demonstrated a strong correlation between monozygotic 
(r= 0.65) than dizygotic (r= 0.48) twins implying that the glycation gap is strongly inheritable (Cohen 
et al. 2006) 
However, our study was limited by the lack of the measurement of the FN3K activity. We attempted 
to determine the FN3K activity using the recently developed colometric assay during the training 
provided by the developers in Belgium, UZ Gent Hospital (Cikomola et al. 2016). However, we 
couldn’t find any enzyme activity using this method even after several troubleshooting efforts. It 
would have been interesting to study the FN3K genotypes, enzymatic activity and the glycation gap 
together. However, previous studies have reported on the activity of FN3K and expression in human 
and animal models (Veiga Da Cunha et al. 2006; Delpierre et al. 2006). The first study to report on 
the reasons behind the varying activity of FN3K enzyme is the study by Delpierre and associates. 
They reported on an association between FN3K enzyme activity and polymorphisms in the FN3K 
gene in a Belgian cohort of 31 type 1 diabetics and 26 controls without any selection in terms of 
age, sex, duration of disease and presence of chronic complications. They described that the CC 
genotype of the G900C was associated with reduced enzymatic activity measured in erythrocytes 
(Delpierre et al. 2006). However this study was limited due to the smaller sample size.  
A second study by a Hungarian research group reported on the correlation of FN3K polymorphisms 
with HbA1c and the onset of DM. They enrolled a cohort of type 2 diabetics (859) and controls (265) 
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and genotyped those with a PCR restriction fragment length polymorphism (RFLP) method and 
determined that the CC genotype of the G900C was associated with later onset of type 2 DM than 
in the case of GC or GG genotypes. They further found that the CC genotype was associated with 
lower levels of HbA1c (Mohás et al. 2010). However, Delpierre et al reported that HbA1c was a poor 
substrate of FN3K due to its N-terminal valine of the β-chains which is glycated during its formation 
(Delpierre et al. 2006). Evidence for the association between the CC genotype and HbA1c was 
obtained from the analysis of a Caucasian cohort (70 diabetics, 35 type 1 DM and 35 type 2 DM) 
and 33 controls which were evaluated using PCR and direct sequencing of the FN3K gene. They 
demonstrated that the CC genotype of the G900C was associated with lower concentration of 
HbA1c (Mosca et al. 2011). 
A further study performed in 314 subjects aged between 57 and 77 years with type 2 DM to 
investigate whether genetic variability in some genes might stimulate the progression of diabetic 
nephropathy and the morbidity and mortality associated with DM found that SNP G900C was 
associated with the progression of diabetic complications including nephropathy and cardiovascular 
morbidity and mortality (Tanhäuserová et al. 2014). Škrha et al conducted a research in 595 White 
(311 men and 284 women) aged between 18 to 93 years. These consisted of 126 healthy controls, 
129 type 1 diabetics and 340 type 2 diabetics. They determined that a decreased concentration of 
soluble receptor for advanced glycation end products (sRAGE) associated with the GG genotype 
of G900C (Škrha et al. 2014). A recent study by Dunmore et al described the association of FN3K 
activity with the glycation gap. They analysed 148 White type 2 diabetics with a mean age of 61.3 
years and reported that the activity and levels of FN3K were significantly higher in the negative 
glycation gap group compared to the positive glycation gap group (Dunmore et al. 2018). 
Taking into consideration that HbA1c is a principal measurement in the calculation of the glycation 
gap, it can be assumed that when the HbA1c levels are high, the value of the glycation gap would 
be high and vice versa (Nayak et al. 2013). Hence, considering our results and findings of the 
studies described above, it can be postulated that the CC genotype of G900C is associated with 
increased FN3K activity in erythrocytes thereby resulting in lower levels of HbA1c and lower 
glycation gap level, whereas the GG genotype of G900C is associated with decreased activity of 
FN3K and higher levels of HbA1c and higher glycation gap. This is demonstrated in Figure 4.1. We 
postulate that the difference in the glycation of proteins as measured by the glycation gap may be 
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due to the variation in FN3K genotypes affecting the activity of the FN3K enzyme thus the levels of 
HbA1c. Therefore, since the glycation gap is an important predictor of risk of DM complications, we 
postulate that the presence of the CC genotype of G900C SNP serves as a defender against the 
risk of developing DM related complications. However, our study was limited as when performing 
real time PCR for SNP genotyping only negative controls were included without positive controls. 
However, our real time data is considered valid since some of our samples were repeated and 
others had been sent for sequencing which served as positive controls for the SNP of interest.  
 
Figure 4.1: Summarized role of FN3K SNP G900C genotypes (CC, GC and GG) 
4.3. Glycation gap correlation analysis 
Furthermore, in our study we found a moderate positive correlation (r=0.51) between the glycation 
gap and HbA1c in the total subjects. This is similar to Cohen who performed a study in 153 type 1 
diabetics aged 15 years and older and calculated the glycation gap as the difference between 
measured HbA1c and HbA1c predicted from the fructosamine based on the HbA1c-Fructosamine 
regression equation. They reported a moderate positive correlation r=0.48 between the glycation 
gap and HbA1c (Cohen et al. 2003). However, Chalew et al performed a study in 62 type 1 diabetics 
and calculated the glycation gap according to Cohen et al (2003) and found a stronger correlation 
CC
Increased FN3K activity
Lower HbA1c levels
Lower glycation gap
Reduced risk of diabetes 
related complications
GC
Intermediate FN3K activity
Intermediated HbA1c levels
Intermediate glycation gap
Intermediate risk of diabetes 
related complications 
GG
Reduced FN3K activity
Higher HbA1c levels
Higher glycation gap
increased risk of diabetes 
related complications
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between the glycation gap and HbA1c (r=0.7) (Chalew et al. 2005). This is contrary to our findings 
and could have been due to the fact that their glycation gap was determined in type 1 diabetics 
whereas ours was determined in type 2 diabetics as well as prediabetic and normal subjects. Also 
their study population was much smaller than ours. 
Paleari et al explored the glycation gap in a selected group of nondiabetic and diabetic subjects, a 
total of 157 subjects (68 males and 89 females) aged between 18 and 75 years and they observed 
a strong positive correlation between the glycation gap and HbA1c in nondiabetic subjects (r = 
0.9468), and a weaker correlation in subjects with HbA1c above the upper limit for non-diabetic 
subjects (r=0.5091) (Paleari et al. 2016). This study supports the findings of our study and provides 
evidence that the weak correlation found between the glycation gap and HbA1c in our study could 
be due to the fact that our nondiabetics and diabetics were analysed together.  Accordingly, the 
findings of the present study imply that HbA1c only explains 51% of the variation in the glycation 
gap while 49% is explained by other confounding factors.  
In our study we found a negative correlation (r= -0.4156, p<0.0001) between the glycation gap and 
fructosamines as expected according to the concept of the glycation gap. Our findings are similar 
to the results of Dziedzic et al who studied 93 healthy subjects (63 women and 30 men), between 
the ages of 18-79 and found a significant negative correlation between fructosamine and the 
glycation gap (r = -0.3, p = 0.003) (Dziedzic et al. 2012). However, our results contradict Rodriguez-
Segade et al who studied 2314 type 2 diabetics (1118 males and 1196 females) with a mean age 
of 59.9 years and determined the glycation gap according to Cohen et al (2003). They found that 
mean fructosamine levels did not differ significantly among the glycation gap groups (Rodriguez-
Segade et al. 2011). Their subjects had diabetic nephropathy which may have affected the levels 
of fructosamines hence no association was found (Rodriguez-Segade et al. 2011). Our results are 
also contrary to what Cosson et al found. They investigated the association of the glycation gap and 
DM complications in 925 type 2 diabetics with a mean age of 57.8 years and found an unexpected 
positive association between the glycation gap and fructosamine (Cosson et al. 2013). This may be 
due hypoproteinaemia resulting from nephropathy and macroprotenuria thereby affecting the levels 
of fructosamines (Cosson et al. 2013). 
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In our study we also found no correlation between the glycation gap and age in the total group. Our 
results contradict those of Dziedzic et al who found a significant positive correlation between age 
and the glycation gap (r= 0.34, p= 0.0006) in 93 healthy subjects (63 women and 30 men) between 
the ages of 18-79 (Dziedzic et al. 2012). This may have been because their glycation gap was only 
determined in healthy subjects in this study, whereas in our study it was determined in diabetic, 
prediabetic and normal subjects. Evidence for this postulation come from the study by Paleari et al 
who explored the glycation gap on a sub-group of 111 healthy subjects (49 females and 62 males)   
and found that the correlation between the glycation gap and age was slightly weaker if non-healthy 
individuals are added into the analysis (r = 0.4486 vs 0.4217, respectively) (Paleari et al. 2016). 
However, these findings contradict the findings of a retrospective cohort study performed in 105 
Korean subjects (mean age of 54.5) with type 2 DM which found a weak negative correlation 
between the glycation gap and age (r = −0.203, P = 0.008) (Kim et al. 2016). 
Further analysis of the glycation gap in our study found that there were several other confounding 
factors independent of glycaemia which need to be taken into consideration. We found that the 
glycation gap correlated significantly with triglycerides and HDL cholesterol. The positive glycation 
gap group had increased levels of triglycerides and decreased levels of HDL cholesterol, whereas 
the negative glycation group had decreased levels of triglycerides and increased levels of HDL 
cholesterol. Low levels of HDL cholesterol and high levels of triglycerides are part of the diabetic 
dyslipidaemia and are a major risk factor for cardiovascular disease in DM (Chehade et al. 2013). 
Low levels of HDL cholesterol and high levels of triglycerides in type 2 DM are associated with the 
risk of macroangiopathy which is linked to cardiovascular diseases (Hermans & Valensi 2018). It 
can be postulated from these findings that the positive glycation gap might be associated with 
diabetic dyslipidaemia. Our findings agree with the findings of the study performed by Cosson et al 
in a cohort of 925 adults with type 2 DM who described that increasing glycation gap tertiles were 
positively associated with dyslipidaemia (Cosson et al. 2013). 
Others have also reported on the association of the glycation gap and DM complications showing 
that type 2 diabetics with high glycation gap are at a high risk of developing microvascular or 
macrovascular complications (Cohen et al. 2003; Rodriguez-Segade et al. 2011; Nayak et al. 2013). 
However, due to the cross-sectional nature of our study, we could not determine whether any 
association with diabetic complications. 
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Chapter 5: Conclusion 
 
In conclusion, our study provided evidence that there are active genetic mechanisms in the 
intracellular RBC compartment resulting in varying activity of the enzyme FN3K, thus affecting the 
levels of HbA1c through the deglycation process. The males in our study had normal BMI and as 
the varying genotypes of SNP G900C was only observed in males, it can be postulated that the 
glycation gap variations observed are independent of BMI. These findings support the protective 
role of the CC genotype of the polymorphism G900C against the effects of non-enzymatic protein 
glycation reactions in DM. Therefore, it can be concluded that identification of the G900C 
polymorphism in an early stage of the disease could be useful, especially in therapeutic decisions 
and prediction of a better prognosis. Furthermore, the present study provided evidence that the 
glycation gap varies with demographic factors and is heritable, clearly showing that the concept of 
the glycation gap needs to be treated with caution and more understanding of it is required. Hence, 
the findings of the present study still need to be confirmed and followed up.  
5.1. Limitations of the study 
Even though our study population was not small, we had a limited number of diabetics (271) 
compared to the normal subjects. When these were then further subdivided according to various 
genotypes of G900C SNP of FN3K, the groups became smaller hence decreasing the statistical 
power of our results. Another limitation was the disproportionate number of females compared to 
males (1073 versus 339). Additionally, the Bellville South population may have high prevalence of 
smokers and smoking may be unseen confounder and we didn’t control for it. Therefore, for the 
glycation gap analysis, the two groups were analysed together which might have influenced our 
results since we found a significant difference in the glycation gap between males and females 
(p<0.0001) which is similar to what other studies have reported (Cohen et al. 2006; Nayak et al. 
2011). A further limitation of our study was that we used fructosamine which is a marker for the 
extracellular glycation and short term glycaemic control for the determination of the glycation gap. 
Fructosamine is known to be affected by proteinuria and protein turn over which may have 
influenced the glycation gap. The high glycation gap observed may reflect the presence of 
proteinuria. Instead we should have used glycated albumin because the percentage of glycated 
albumin is not influenced by the albumin concentration (Yeungb et al. 1992).  
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Furthermore, for the glycation gap analysis the normal, pre-diabetic and diabetic subjects were 
analysed together because further subdivision of these glycaemic groups into glycation gap 
categories could have resulted in smaller numbers making our results unreliable. However, we 
found no significant difference observed in the glycation gap among the glycaemic groups (normal, 
pre-diabetic and diabetic). Another major limitation of the present study was we didn’t control for 
the glycation gap confounding factors including BMI, waist and hip circumference, HDL cholesterol 
and triglycerides which might have influenced our results. Hence, no conclusion could be made 
regarding the glycation gap in the present study as it was not known if our findings were independent 
of these factors as they significantly correlated with the glycation gap.  
5.2. Clinical implications 
There is considerably less evidence about various genotypes of FN3K SNPs that might confer 
protection against DM and its related complications. Our findings are very useful in research 
because they show evidence that FN3K has a protective role in type 2 DM. The association of the 
CC genotype of G900C with low levels of the glycation gap confirm that FN3K can significantly 
reduce the risk of developing diabetic related complications. Furthermore, we provided evidence 
that the glycation gap can be an important research tool that can be used to evaluate underlying 
factors beyond glycaemic control which might be influencing the development of diabetic 
complications. Therefore since the glycation gap is easily accessible it may be useful in DM 
management and could help with developing new therapeutic approaches and allow consideration 
of targeted interventions.  
 
5.3. Recommendation for future studies  
We recommend that larger prospective studies are necessary to investigate the effects of FN3K 
genotypes on the glycation gap. It would be interesting to correlate FN3K genotypes with enzyme 
activity and the glycation gap in diabetics and those with various diabetic microvascular and 
macrovascular complications. This is necessary for better understanding of the role of this various 
FN3K genotypes in DM and its related complications as well as its possible role in the management 
of the disease. Furthermore, future studies can investigate if the presence of specific genotypes in 
FN3K SNPs is associated with the development of diabetic complications and if they can help in 
early diagnosis of complications resulting in a better prognosis of the disease. Although several 
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studies have shown that the glycation gap is consistent over time within individuals, it is associated 
with DM microvascular and macrovascular complications as well as DM related mortality.  It has 
also been shown that the glycation gap is associated with several demographic factors. In the 
present study we confirmed that it is affected by the genotypes of G900C SNP of FN3K. Therefore, 
there is a huge “gap” that still needs to be filled and more studies should be performed in order to 
understand the mechanisms behind this phenomenon independent of the confounding factors. 
Clinical trials could be necessary to help determine how best to use the glycation gap in clinical 
practice. Animal model studies could be necessary to explore the therapeutic possibilities of FN3K 
enzyme for DM and its complications. 
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Appendix B: Salt Extraction method (Laboratory Protocol 2014) 
(Adapted from http://www.liv.ac.uk/~kempsj/IsolationofDNA.pdf). 
 
Day 1: Day 2: 
Work on ice  
Add to 50 ml tubes:  
• 1 - 5 ml blood  
• 10 ml lysis buffer at 4°C  
• [OR 10 ml blood + 30 ml lysis buffer]  
 
Vortex, put on ice for 5 min, repeat 3x  
Spin 1,500 rpm, 10 min at 4 °C  
Discard supernatant  
KEEP PELLET  
Add to pellet:  
• 10 ml PBS (to rinse)  
 
Vortex  
Spin 1,500 rpm, 10 min at 4 °C  
Discard supernatant  
If pellet is still red, repeat:  
Add 10 ml PBS  
Vortex  
Spin 1,500 rpm, 10 min at 4 °C  
Discard supernatant  
KEEP PELLET  
Dissolve pellet in:  
• 3 ml nucleic lysis buffer  
• 30 μl proteinase K (10 mg/ml)  
• 300 μl 10 % SDS  
 
Vortex  
Incubate overnight at 55°C (waterbath 
full)  
Don’t work on ice  
Add to volume in tube:  
• 1 ml 6 M NaCl  
 
Vortex well, but not too vigorously  
Spin 2500 rpm for 30 min  
KEEP SUPERNATANT FLUID  
Shake well for 15 sec  
Spin 2500 rpm for 30 min  
KEEP SUPERNATANT FLUID  
To precipitate DNA add to 
supernatant:  
• two volumes 100 % ethanol at -20 
°C  
 
(~ 5 ml supernatant + 10 ml ETOH)  
Tilt to precipitate DNA  
Take out DNA and put into tube with 
1ml 70 % ETOH at -20 °C  
Spin at max speed for 30 min (to get 
rid of last salt; supernatant will have 
salt in if any)  
Discard supernatant  
KEEP PELLET  
Tip tube dry on paper towel  
Dissolve DNA pellet in::  
• 100 - 200 μl distilled water  
 
(depending on size of pellet)  
Put overnight on turning apparatus to 
dissolve  
 
Day 3:  
Read ODs/Nanodrop  
OD 260/280 ratio  
Aliquot and freeze at -20 °C  
Keep record:  
Volume blood used  
Volume of final DNA sample  
Concentration of final DNA sample/μl  
DNA concentration per starting 
material  
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Salt extraction method (Buffers and reagents needed) 
Buffers/Solutions 
needed  
Nuclear lysis buffer  PBS  
1. Preliminary buffers  
2. Lysis buffer  
3. Nuclear lysis 
buffer  
4. 6 M NaCl (70.13 
g/200 mL)  
5. 10 % SDS (10 
g/100mL)  
6. PBS  
7. Proteinase K  
10 mM Tris (1 ml 
from 1 M stock)  
400 mM NaCl (2.3 g 
NaCl)  
2 mM EDTA (2 ml 
from 100 mM stock)  
Make up 100 ml  
pH to 8.2  
0.2 g KCl (2.68 mM)  
8.0 g NaCl (136 mM)  
0.2 g KH2PO4 (1.47 mM)  
1.15 g Na2HPO4 (8.1 mM)  
Add components one at a 
time to 900 ml of distilled 
water  
Stir to dissolve  
pH to 7.4  
Make up to 1 L with distilled 
water  
 
Preliminary buffers  6 M NaCl  Proteinase K  
1 M stock NH4 Cl  
1 M stock KHCO3  
100 mM stock EDTA  
 
70.13 g/200 
ml/saturated  
10 mg/ml proteinase K  
Lysis buffer 10 % SDS   
155 mM NH4 Cl 
(15.5 ml from 1 M 
stock)  
10 mM KHCO3 (1 ml 
from 1 M stock)  
0.1 mM EDTA (100 
μl from 100 mM 
stock)  
Make up to 100 ml  
pH to 7.4 
 
10 g/100ml   
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Appendix C: Consent Form 
 
PARTICIPANT INFORMATION AND INFORMED CONSENT FORM FOR 
RESEARCH INVOLVING GENETIC STUDIES 
 
TITLE OF RESEARCH PROJECT: PROGRESSIVE RESEARCH ON RISK 
FACTORS OF TYPE 2 DIABETES AND CARDIOVASCULAR DISEASES IN 
SOUTH AFRICA 
 
REFERENCE NUMBER: 
 
PRINCIPAL INVESTIGATORS: Professor Tandi Matsha (Cape Peninsula 
University of Technology) 
Professor Rajiv Erasmus (Stellenbosch University) Professor Andre Kengne 
(SA Medical Research Council) 
 
Project manager:  Dr Gloudina Maria Hon (Cape Peninsula University 
of Technology) 
 
ADDRESS: Obesity and chronic diseases of lifestyle Department of 
Biomedical Sciences Faculty of Health & Wellness Sciences 
Cape Peninsula University of Technology, Bellville 
 
CONTACT NUMBER: Prof T Matsha 021 959 6366 or email: 
matshat@cput.ac.za 
 
Ethics approval:  Cape Peninsula University of Technology Ethics 
Reference number: CPUT/SW-REC 2015/H01 
University of Stellenbosch Ethics Reference number: N14/01/003 
 
We would like to invite you to participate in a research study that involves 
genetic analysis and possible long-term storage of blood or tissue specimens. 
Please take some time to read the information presented here which will 
explain the details of this project. Please ask the study staff or doctor any 
questions about any part of this project that you do not fully understand. It is 
very important that you are fully satisfied that you clearly understand what this 
research entails and how you could be involved. Also, your participation is 
entirely voluntary and you are free to decline to participate. If you say no, this 
will not affect you negatively in any way whatsoever. You are also free to 
withdraw from the study at any point, even if you do agree to take part initially. 
 
This research study has been approved by the ethics Faculty of Health & 
Wellness Sciences of the Cape Peninsula University of Technology and it will 
be conducted according to  international and locally accepted ethical 
guidelines for research, namely the Declaration of Helsinki, and the SA 
Department of Health’s 2004 Guidelines: Ethics in Health Research: 
Principles, Structures and Processes. 
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Genetic material, also called DNA or RNA, is usually obtained from a small 
blood sample. Occasionally genetic material is obtained from other sources 
such as saliva or biopsy specimens. (A biopsy is a tiny piece of tissue that is 
cut out e.g. from the skin or from a lump, to help your doctor make a 
diagnosis.) Genes are found in every cell in the human body. Our genes 
determine what we look  like  and sometimes what kind of diseases we may 
be susceptible to. Worldwide, researchers in the field of genetics are 
continuously discovering new information that may be of great benefit to 
future generations and also that may benefit people today, who suffer from 
particular diseases or conditions. 
 
  
 
This research study seeks to address the increasing problem of diabetes and 
cardiovascular diseases such as heart attack and stroke amongst the mixed 
ancestry or coloured population of South Africa. In this study we shall identify 
people with diabetes and those at high risk of diabetes as well as investigate 
the environmental and genetic risk factors that predispose some individuals to 
the development of diabetes and cardiovascular diseases. Examples of 
environmental factors include body weight, diet, and physical activity. 
Additionally, this project aims to investigate whether oral health is a risk factor 
for diabetes and cardiovascular diseases. In this study we shall investigate 
whether some individuals have early cardiovascular diseases by using an 
ultrasound machine. This project also aims to collect genetic material (blood) 
to analyze for certain variants and to store excess material for future research. 
When a large group of patients with similar diseases has been collected, 
meaningful research into the disease processes may become possible. 
 
  
 
Our research team has previously conducted a similar research study 
involving the coloured community and found out that more that 18 out of 100 
individuals had diabetes but did not know. We also found that some of the risk 
factors associated with diabetes in other populations were not necessary the 
same as those affecting the coloured population of South Africa. You have 
therefore been invited to take part in this research study to assist in 
establishing the risk factors for diabetes and cardiovascular diseases affecting 
the coloured people of South Africa. 
 
  
 
A. You will be requested to provide information about your medical 
history, family history and information on eating, drinking and smoking habits. 
Completion of the questionnaire will take no longer than 30 minutes. 
B. You shall be requested to provide a record of the medication you are 
currently taking, therefore if you are taking chronic medication, you shall be 
requested to provide this to the research team to record the medication. 
C. Measurement such as weight, height, waist and hip will be done. 
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D. Fasting Venous Blood (20ml) will be collected thereafter you will be 
asked to drink a glucose solution (glucose content 75g). After two hours 
another venous blood (10ml) will be collected. The blood will be used to 
determine whether you have diabetes or you are at high risk for developing 
diabetes. 
E. The other tests that will be determined from your blood sample are:  
Cholesterol, triglycerides, creatine levels to assess your kidney function, liver 
enzymes to assess your liver, and biochemical markers for inflammation. 
F. A finger prick blood sample (a drop of blood), to be taken at the same 
time of the first venous blood sample, may also be required from you. The 
finger prick blood sample will be used to test for diabetes or the risk of 
developing diabetes on a point-of-care test instrument. Researchers will 
compare the finger prick point-of-care diabetes test with that of the send away 
venous blood laboratory test and would be able to establish whether the point-
of-care test provides the same accurate results as that of 
the laboratory. Point-of-care testing may in the future be used to provide fast 
and accurate results without the need to send blood away to a laboratory for 
processing. This may be of benefit to people undergoing testing for diabetes 
as results would be available within a few minutes. 
G. The remainder of the blood sample will be used for genetic and future 
research studies. The serum and DNA may be stored for several years until 
the technology for meaningful analysis becomes available. No pharmaceutical 
agent (medication) will be tested in the study. 
H. For oral health,  research  study  personnel  will  extract  wooden  
toothpick,  flocked  brush,  and mouthwash saliva samples from you to test for 
the presence of Porphyromonas gingivalis as an indicator for periodontal 
disease. Flocked brush and wood toothpick sampling will involve inserting 
devices in the subgingival crevice between the last upper premolar and the 
first upper molar. The device will sweep down the anterior surface of the first 
upper molar with the direction of motion away from the gum to minimize any 
potential discomfort. Mouthwash sampling will involve rinsing with 10 ml 
sterile saline solution for 20 seconds. 
I. Early cardiovascular diseases will be performed by means of an 
ultrasound machine. 
J. The research team will follow up on you on a yearly basis and some of 
these test may be repeated. The investigators wish to follow you up for your 
entire life. In the unfortunate event that you are deceased during the study 
period. The study team will review stats SA data and/or medical records to 
ascertain whether the cause of death was due to diabetes or cardiovascular 
diseases. . If you do not wish to be followed up on a yearly basis and your 
Statistics SA and/or medical records not to be accessed in the unfortunate 
event that you are deceased whilst being a participant in the study, you will 
have an opportunity to request that it be not accessed when you sign the 
consent form. 
K. Radio imaging techniques will be done on consenting subjects. These 
include (i) ultra sound to assess whether you have signs of early 
cardiovascular diseases, (ii) computed tomography scan (CT-scan) to 
accurately assess the fat content that is dangerous for cardiovascular 
diseases (iii) Dual-energy X-ray absorptiometry (DXA) devices will be used to 
study the morphology of the liver. These radio imaging techniques involve 
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radiation which can be harmful if one is exposed excessively. For this study a 
low dose radiation will be used for acquisition of the images thereby 
minimizing radiation exposure to the participant. . If you do not wish to 
undergo any of these radio imaging techniques, you will have an opportunity 
to decline when you sign the consent form. 
L. An eye examination will be done to test your eye vision and any other 
abnormalities inthe eye. For this examination, drops placed in your eyes 
widen (dilate) your pupils to allow the doctor to better view inside your eyes. 
The drops may cause your close vision to blur for a short while. 
 
  
 
A slight bruising might occur after blood has been drawn from the arm but this 
will heal quickly. After the administration of the glucose solution, you may feel 
nauseous and dizzy in which case you must notify the medical personnel. A 
medical nurse or doctor will be present on all occasions. You may also learn 
that you have diabetes, in which case you will be referred to your health care 
giver with the results for further treatment and management. If during the 
study it is discovered that you have changes in your genes that may lead to a 
serious disease, a genetic counsellor at the expense of the principal 
investigators will counsel you. Radio imaging techniques such as the CT-scan 
involves radiation which can be harmful if one is exposed excessively. For this 
study  a low dose radiation will be used for acquisition of the images thereby 
minimizing radiation exposure to the participant. 
 
  
 
Your personal results will be made known to you only if they indicate that you 
may: 
• Have diabetes, thereafter, you will be referred to your local health 
centre or general practitioner for further investigations and treatment. 
• Have a condition or predisposition to developing diabetes that is 
treatable or avoidable 
e.g. by a lifestyle modification. 
• Need genetic counselling. 
 However, participants with normal results who wish to know their 
results are free to contact the research team and their results will be given 
upon written request. 
 
  
 
The blood samples may be stored indefinitely to accommodate new 
technologies that may develop. In the event that a technology is not available 
in South Africa to analyse your blood sample, your blood specimen may be 
sent to another country with the technology either now or at a later date. 
However, if your specimen is to be sent to another country, permission to do 
so will be sought from relevant bodies. Your blood specimen will be stored at 
the Cape Peninsula University of Technology. 
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Your   blood    will    only    be    used    for    genetic    research    that    is    
directly    related    to Diabetes and cardiovascular diseases. Also if the 
researchers wish to use your stored blood for additional research in this field 
they will be required to apply for permission to do so from the ethics Faculty of 
Health & Wellness Sciences of the Cape Peninsula University of Technology. 
If you do not wish your blood specimen to be stored after this research study 
is completed you will have an opportunity to request that it be discarded when 
you sign the consent form. 
 
  
 
Your identity will be recorded once and kept confidential throughout. This is to 
allow the principal investigators to convey information that may be beneficial 
to you. Access will be limited to the principal investigators by assigning a 
special study code to all your data and blood samples. This means that your 
sample will be identified with a special study code that will remain linked to 
your name and contact details. However, during the entire research study, 
your blood specimens will be anonymised and the research staff won’t be able 
to associate it with your name and contact details. You shall also  be supplied 
this code so that if at anytime the investigators need to contact you, you may 
only identify yourself using your special code. Any scientific publications, 
lectures or reports resulting from the study will not identify you. 
 
Some insurance companies may mistakenly assume that taking part in 
research indicates a higher risk for disease. Thus no information about you or 
your family will be shared with such companies. 
 
  
 
You will not be paid to take part in this study although your out-of-pocket 
expenses may be reimbursed. The expenses that will be covered by the 
research team are those that include transportation to a hospital radiography 
department should you consent to radio imaging. 
 
  
 
  
 
You should inform your family practitioner or usual doctor that you are taking 
part in a research study. You can contact 
  
Prof T Matsha at 021 959 6366 or matshat@cput.ac.za, 
If you have any further queries or encounter any problems, you can also 
contact the Cape Peninsula University of Technology Health and Wellness 
Sciences Research Ethics Committee, 
Chairperson: Prof Engel-hills at 0219596570 or EngelhillsP@cput.ac.za or 
 
You will receive a copy of this information and consent form for your own 
records if it is requested. 
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By signing below, I …………………………………..…………. agree to take part 
in a research project that includes genetic research study entitled 
(PROGRESSIVE RESEARCH ON RISK FACTORS OF TYPE 2 DIABETES 
AND CARDIOVASCULAR DISEASES IN SOUTH AFRICA). 
I declare that: 
 
• I have read or had read to me this information and consent form and it 
is written in a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been 
adequately answered. 
• I understand that taking part in this study is voluntary and I have not 
been pressurised to take part. 
• I have received a signed duplicate copy of this consent form for my 
records. 
 
 
  
 
I agree that my blood or tissue sample can  be stored  indefinitely after the 
project is completed but that it is anonymised with all possible links to my 
identity removed, and that the researchers may then use it for additional 
research in this or a related field. Once my sample is anonymised, my rights 
to that sample are waivered. My sample may be shipped to another laboratory 
in SA or abroad to be used in other research projects in this or a related field 
 
OR 
 
I agree that my blood or tissue sample can be stored indefinitely, but I can 
choose to request at any time that my stored sample be destroyed. My 
sample will be identified with a special study code that will remain linked to my 
name and contact details. I have the right to receive confirmation that my 
request has been carried out. 
OR 
Please destroy my blood sample as soon as the current research project has 
been completed. 
  
 
  
 
 
I consent that the research team may follow me up for yearly check-up AND in 
the unfortunate event that I am deceased whilst still part of the study, I 
consent that the team may access Statistics SA and/or my medical records to 
ascertain whether the cause of my death was due to diabetes or 
cardiovascular diseases. 
 
OR 
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I do not consent to follow me up for yearly check-up BUT in the unfortunate 
event that I am deceased whilst still part of the study, I consent that the team 
may access Statistics SA and/or my medical records to ascertain whether the 
cause of my death was due to diabetes or cardiovascular diseases. 
 
OR 
 
I do not consent to follow me up for yearly check-up AND in the unfortunate 
event that I am deceased whilst still part of the study, I do not consent that the 
team accessing Statistics SA and/or my medical records to ascertain whether 
the cause of my death was due to diabetes or cardiovascular diseases. 
 
 
  
 
□ I consent to ultra sound techniques to assess if I have early 
cardiovascular diseases 
□ I do not consent to ultra sound techniques that assess if I have early 
cardiovascular diseases 
AND 
 
□ I  consent  computed  tomography  scan  (CT-scan)  to  accurately  
assess  the  fat  content  that  is dangerous for cardiovascular diseases 
 
□ I do not consent to computed tomography scan (CT-scan) that 
accurately assess the fat content that is dangerous for cardiovascular 
diseases 
 
AND 
 
□ I consent to Dual-energy X-ray absorptiometry (DXA) used to study 
body composition. 
□ I do not consent Dual-energy X-ray absorptiometry (DXA) used to 
study body composition 
  
Signed at (place) .......................................................... on (date)
 ...................................................... 
 
 
 
 
  
 
 
Finger print 
  
.........................................................
 .......................................................................... 
Signature of participant Signature of witness 
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I (name) ………………………………………………… declare that: 
 
• I explained the information in this document to 
…………………..……………... 
• I encouraged him/her to ask questions and took adequate time to 
answer them. 
• I am satisfied that he/she adequately understands all aspects of the 
research as discussed above. 
• I did/did not use a interpreter.  (If a interpreter is used then the 
interpreter must sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) 
…………....……….. 2016. 
 
 
............................................................................
 .......................................................................... 
Signature of investigator Signature of witness 
 
  
 
I (name) ………………………………………………… declare that: 
 
• I assisted the investigator (name) …………………………. to explain the 
information in this document to (name of participant) 
…………………………….. Using  the language medium of Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to 
answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
answered. 
 
 
Signed at (place) ......................…........…………….. on (date) 
…………....……….. 2016. 
 
 
............................................................................
 .......................................................................... 
Signature of interpreter Signature of witnes
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